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ABSTRACT OF THE DISSERTATION 
Enzymology of DHHC-mediated Protein S-Acylation 
By 
Benjamin C. Jennings 
Doctor of Philosophy in Biology and Biomedical Sciences  
(Biochemistry) 
Washington University in St. Louis, 2011 
Professor Maurine E. Linder, Chair 
 
 Protein S-acylation is the post-translational modification of proteins with long-
chain fatty acids at cysteine residues via a thioester linkage.  The most commonly 
attached lipid is 16-carbon palmitate, thus the process is often called palmitoylation.  
Unlike other lipid modifications, protein S-acylation is reversible.  Consequently, cells 
use acylation/deacylation cycles to regulate protein localization, stability, and activity.  A 
family of integral membrane enzymes called DHHC proteins because of a conserved 
Asp-His-His-Cys motif, catalyze protein S-acylation within cells.  DHHC proteins have 
been associated with human diseases including cancers, Huntington’s disease, and mental 
retardation.  However little is known about their function or regulation.  This work 
focuses on developing a better mechanistic understanding of mammalian DHHC proteins. 
 To facilitate biochemical characterization, a protocol was developed to express 
and purify recombinant DHHC proteins from insect cells using recombinant baculovirus.  
Protein S-acyltransferase (PAT) activity was measured by in vitro assays using 
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radiolabeled palmitoyl-coenzyme A and purified protein substrates.  Assay conditions 
were optimized to maximize PAT activity.   
In vitro, both protein substrate and DHHC protein incorporated palmitate.  This 
latter process is termed enzyme autoacylation and lead to the hypothesis that DHHC 
proteins use a two-step ping-pong mechanism with an acyl-enzyme transfer intermediate.  
A fluorescent peptide, high performance liquid chromatography-based PAT assay was 
developed for classic steady-state kinetic experiments.  Single turnover assays supported 
the hypothesis with radiolabeled fatty acid transferring from acyl-DHHC to protein 
substrate.  Unexpectedly, these investigations also revealed that DHHC proteins display 
different acyl-CoA chain length preferences.  A mechanism for this difference is 
proposed and tested.  
 Inhibitors of DHHC proteins will be useful tools for studying protein S-acylation 
within cells and as potential pharmaceutical agents.  Others in the field have identified 
classes of compounds that reduce cellular S-acylation.  Four representative compounds 
and the known palmitoylation inhibitor 2-bromopalmitate (2BP) were tested for 
inhibition of DHHC-mediated S-acylation with four DHHC proteins and their cognate 
substrates in vitro.  Two compounds, 2BP and 2-(2-Hydroxy-5-nitro-benzylidene)-
benzo[b]thiophen-3-one (compound V), inhibited autoacylation and acyl-transfer of all 
DHHCs tested.  These compounds were further characterized for reversibility and time-
dependence.  Given their modest potency and lack of specificity, new screens for 
inhibitors of DHHC proteins are needed.  
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Chapter 1 
Introduction  
 Cells typically use one of three mechanisms to anchor proteins at membranes: 
insertion with transmembrane domains, interaction with other membrane components, or 
covalent modification with lipids.  This last process, called protein lipidation, occurs 
through multiple mechanisms and involves a variety of lipids including fatty acids, 
isoprenoids, and cholesterol (Table 1.1).  Lipid modifications can be divided into two 
broad categories: those that occur in the cytoplasm or on the cytoplasmic face of 
membranes, and those that occur in the lumen of the secretory pathway (1).  Lipid 
modifications on secreted proteins include glycosylphosphatidyl-inositol (GPI) anchors 
and fatty acylation including O-acylation and N-palmitoylation; however they are beyond 
the scope of this discussion and one is referred to reviews elsewhere (2-7).  Lipid 
modifications occurring in the cytoplasm include protein S-acylation, N-myristoylation, 
and prenylation.  While S-acylation is the main focus of these studies, it often occurs 
adjacent to N-myristoylation and prenylation sites; therefore, they will also be briefly 
discussed.  
 
Protein S-acylation 
 Protein S-acylation is the post-translational modification of proteins with long-
chain fatty acids at cysteine residues via a thioester linkage.  The most common fatty acid 
donor is 16-carbon palmitoyl-coenzyme A (palmCoA), so the process is often called 
protein palmitoylation.  However, a second type of palmitoylation, N-palmitoylation, 
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exists so the term S-acylation will be used.  N-palmitoylation occurs on secreted proteins 
and this modification is mediated by a separate group of enzymes, membrane-bound O-
acylation transferases (MBOATS), which are structurally distinct from protein S-
acyltransferases (PATs, (8).  The only known N-palmitoylated protein that is not secreted 
is Gαs, which is N-palmitoylated on Gly2 by an unknown mechanism and S-palmitoylated 
on Cys3 (9).      
 Protein modification with fatty acids was the first covalent lipid modification 
described in eukaryotic cells (10).  In 1971, two groups reported that highly purified brain 
myelin proteolipid protein contained covalently attached fatty acids (11, 12).  Stoffyn and 
Folch-Pi further characterized the lipids as attached via an ester linkage (either oxy- or 
thio-ester) and a mixture of palmitate, stearate, and oleate (11). These properties are 
consistent with our current understanding of protein S-acylation.  However, their work 
was largely forgotten and in 1979 S-acylation was rediscovered for viral membrane 
glycoproteins (13) and soon thereafter as a widespread modification of eukaryotic 
proteins (14).  Today, thanks in particular to advances in chemical biology and mass 
spectrometry, palmitoyl-proteomes have been analyzed for a number of cell lines.  
Revealing both novel and known S-acylated proteins, these techniques detect hundreds of 
modified proteins and in some cases, identify the site(s) of modification (15-20).  
 Although protein S-acylation was discovered first, the molecular identity of the 
enzymes responsible remained unknown until the last ten years.  Traditional biochemical 
approaches at determining the molecular identity of PATs were unsuccessful.  Gutierrez 
and Magee detected a membrane localized PAT activity from mouse fibroblasts that co-
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fractionated with Golgi markers and S-acylated N-ras, then called p21N-ras (21).  
Similarly, Berthiaume and Resh partially purified PAT activity from bovine brain that in 
vitro acylated N-myristoylated Fyn and behaved as a membrane-bound enzyme (22).  Liu 
and coworkers also partially purified a palmitoyltransferase activity from rat liver that in 
vitro acylated H-ras using palmCoA as a substrate (23).  However, subsequent 
sequencing and immunoblotting determined that Liu and coworkers had purified 
peroxisomal 3-oxoacyl-CoA thiolase A (24), an enzyme involved in β-oxidation of fatty 
acids, and unlikely a bona fide PAT.  The ability of thiolase A to catalyze S-acylation was 
dependent on imidazole in the PAT assay, which was present in the buffer of the His-
tagged Ras substrate.  Since then, a number of thiolases have been shown to catalyze 
acylation in the presence of imidazole (25).  Dunphy and coworkers from our group also 
partially purified detergent-solubilized PAT activity from bovine brain membranes.  This 
activity was not contaminated with thiolase, was enriched in plasma membranes, and was 
capable of acylating G-protein α-subunits (26).  However, none of these groups could 
obtain highly purified preparations of detergent-solubilized PAT to permit molecular 
identification.  Labile activity, poor recovery from conventional chromatographic steps, 
and sensitivity to freeze/thaw cycles limited further purification (10, 22).  Of note, the N-
ras PAT in Golgi membranes and the Gα-subunit PAT in plasma membranes suggested 
multiple enzymes with different subcellular localizations, which is consistent with our 
present understanding of DHHC proteins (27). 
 Prior to the determination that DHHC proteins account for the majority of PAT 
activity in cells (16), some questioned whether S-acylation was enzyme catalyzed. 
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Nonenzymatic S-acylation, also called autoacylation, can occur by incubating a thiol-
containing peptide or protein with long-chain acyl-CoAs in the context of a hydrophobic 
surface.  Known S-acylated proteins that demonstrate autoacylation in vitro include G-
protein α subunits (28), myelin proteolipid proteins lipophilin (29) and P0 (30), rhodopsin 
(31), and Bet3 (32).  Supporting this nonenzymatic mechanism, in vitro acylation of these 
proteins displayed similar properties to acylation observed in vivo, including fatty acid 
attachment at similar cysteine residues, enhancement of acylation on N-myristoylated 
versus non-myristoylated proteins, and reactions occurring at physiological pH and 
temperature.  While Gαs was shown to nonenzymatically S-acylate in vitro (33), 
subsequent work showed that this occurred at Cys160 and not the physiological Cys3 site 
(34).  For lipophilin, rhodopsin, and Gα subunits, the authors determined that 
autoacylation kinetics fit the Michaelis-Menten equation, saturating at high palmCoA 
concentrations, and reported Km values of 50, 40, and 450 µM palmCoA, respectively 
(28, 29, 31).  However, these Km values more likely reflected the concentration of 
detergent micelles in the assay (50, 50, and 400 µM, respectively) and thus call into 
question the relevance of these observations for the following reasons.  In vitro in 
aqueous buffer palmCoA forms micelles around 4 µM (CMC = 3-4 µM at 10 mM KCl, 
no detergent; (35)) and the in vivo predictions of free long-chain acyl-CoA 
concentrations are around 0.2 µM after factoring in sequestration by acyl-CoA binding 
protein (ACBP) and fatty acid binding protein (FABP) (36).  The abundant cytosolic 
protein ACBP binds long-chain acyl-CoAs with high nanomolar affinity and greatly 
increases the half-times for spontaneous S-acylation of proteins to tens of hours (37) 
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whereas in cells, acylation half-times are a few minutes (6 min H-ras, 1 min N-ras (38)).  
In contrast, partially purified Gα PAT activity (26) remains active in the presence of 
physiological concentrations of ACBP and acyl-CoA and likely represents the 
predominant mechanism of S-acylation in vivo (39).  Nonenzymatic autoacylation 
requires the cysteine residue and palmCoA present at an aqueous-hydrophobic interface 
(40, 41); thus the saturation observed in the kinetics may be more a measure of the 
amount of this reactive surface than of the binding interaction between palmCoA and 
protein substrate.  It is possible that nonenzymatic acylation of some proteins is 
physiologically relevant (e.g. Bet3 (32)), although DHHC proteins account for most 
cellular S-acylation (16).  When assaying in vitro DHHC-catalyzed acylation of 
substrates, and especially for proteins similar to Gα subunits or at high acyl-CoA 
concentrations, nonenzymatic substrate autoacylation must be controlled for. 
 
Dual Lipidation 
 Although protein S-acylation can occur on otherwise completely cytoplasmic 
proteins, it often occurs in the context of other membrane association signals and in some 
cases, even on integral membrane proteins.  To date, no well-defined amino acid 
recognition sequences are known for protein S-acylation sites except the presence of a 
free cysteine sulfhydryl.  Nevertheless, software programs for the prediction of S-
acylation sites have been developed and work with varying success (42-47).  However, 
validation by biochemical experimental methods is recommended.  These programs are in 
part based on the fact that protein S-acylation sites are frequently adjacent to other 
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membrane anchoring signals.  The two-hit model, which has other names including the 
two-signal hypothesis and the kinetic trapping model, attempts to explain this occurrence 
of adjacent membrane anchoring signals.  This model states that one membrane 
anchoring signal, such as N-myristoylation, prenylation, or a polybasic sequence, allows 
a protein to sample different cellular membranes because of a reasonably fast off rate 
from the membrane.  Supporting this part of the model, peptides that were either N-
myristoylated (48) or prenylated (49, 50) lacked sufficient binding energy to stably 
anchor them to the membrane.  The model goes on to state that when a protein acquires a 
second hit, the dually anchored protein is trapped at the membrane due to a very slow off 
rate (1, 49, 51).  Reversible protein S-acylation is often the ‘second hit’ allowing cycles 
of acylation/deacylation to dynamic regulation membrane association (38).  While 
several ‘first hit’ anchoring signals exist, I want to highlight two: N-myristoylation and 
prenylation.  In addition, I will describe the kinetic mechanism for the enzymes that 
mediate these lipid modifications so that they can be compared with the proposed 
catalytic mechanism for DHHC proteins.  
 
Myristoylation 
 Protein N-myristoylation is the covalent attachment of 14-carbon myristate to N-
terminal glycine residues via an amide linkage (Table 1.1).  In 1982, myristoylation was 
originally described as an unusual blocking group on N-terminal residues that was 
resistant to Edman degradation and that required high acetonitrile concentrations to elute 
from HPLC columns (52, 53).  Following removal of the initiator methionine residue by 
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methionine aminopeptidase, myristoyl-CoA:protein N-myristoyltransferase (NMT) 
catalyzes the irreversible attachment of myristate.  S. cerevisiae (54) and Drosophila (55) 
each contain one NMT gene, which is essential for survival, whereas vertebrates have two 
NMT genes, NMT1 and NMT2.  NMT is a soluble, monomeric enzyme recognizing a 
substrate consensus sequence of Gly2-X-X-X-Ser/Thr6- at the extreme N-terminus.  
Relevant examples include a subset of G-protein α subunits (i, o, z, t, and g) and the Src 
family of tyrosine kinases (Lck, Fyn, Src, Lyn, etc) (56).  These and most known 
examples of myristoylation occur co-translationally, however, a growing number of post-
translational myristoylation events have been described.  In apoptotic cells, activated 
caspases cleave proteins exposing internal “cryptic” myristoylation consensus sequences 
(57).  Examples include BID (58), β-actin (59), gelsolin (60), and p21-activated kinase 2 
(PAK2) (61).  In the case of BID, myristoylated caspase-truncated BID was more 
effective than non-myristoylated at releasing cytochrome c from mitochondria (58). 
 Although NMT uses acyl-CoAs and protein substrates similar to DHHC proteins, 
its kinetic mechanism is likely different.  Initially a ping-pong mechanism was suggested 
for yeast NMT because incubation of purified NMT with [14C]-myristoyl-CoA and 
hydroxylamine treatment demonstrated a covalent ester-linked acyl-enzyme (62, 63).  
However, subsequent Lineweaver-Bruke analysis (64, 65) and crystal structures with and 
without bound substrates (66-68) support a sequential ordered Bi Bi mechanism.  
Myristoyl-CoA binds first followed by protein substrate for a direct nucleophilic 
addition-elimination reaction, which is followed by the release of CoA and subsequent 
release of the N-myristoylated protein.  Crystal structures also revealed that specificity 
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for 14-carbon acyl-CoAs is achieved by measuring the fatty acid length between an 
oxyanion hole binding the carbonyl and the floor of the hydrophobic pocket.  In addition, 
a hydrophobic groove induces bends in myristate that further restrict acyl-chain 
saturation and branching (69).  
 
Prenylation  
 Protein prenylation is the covalent attachment of an isoprenoid lipid to C-terminal 
cysteine residues via a thioether linkage (Table 1.1).  Three prenyltransferases are known: 
farnesyltransferase (FTase) and geranylgeranyltransferase type I (GGTase-I), together 
termed the CaaX prenyltransferases, and protein GGTase-II (or RabGGTase).  FTase 
transfers the 15-carbon farnesyl-group using farnesyl diphosphate (FPP) as a lipid source 
whereas GGTases utilitize geranylgeranyl diphosphate.  FTase and GGTase-I have a 
consensus recognition sequences of -CaaX where C is the modified cysteine residue, ‘a’ 
are typically small aliphatic residues, and X is the terminal residue that helps specify 
which enzyme recognizes the site.  After lipidation, most prenylated proteins undergo 
removal of the aaX tripeptide by the protease Rce1 and are then carboymethylated on the 
prenylated cysteine residue by isoprenylcysteine carboxyl methyltransferase (Icmt).  
Farnesylation was first identified in 1978 on a fungal mating factor (70).  In 1989, 
oncogenic Ras proteins were first described as farnesylated (71) and the next year, FTase 
was identified by multiple groups as the enzyme responsible for this modification (72, 
73).  FTase is a heterodimer composed of two subunits encoded by RAM1 and RAM2, an 
essential gene in yeast (74, 75).  
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 The kinetic mechanism of FTase is well characterized with all rate constants 
known, in part because it is a stable, soluble enzyme and crystallographic studies have 
produced structures of all major steps along the reaction pathway (76).  FTase uses a 
sequential ordered Bi Bi reaction mechanism.  FPP binds first followed by the CaaX 
substrate to form a ternary complex.  A required Zn2+ ion helps orient and stabilize the 
cysteine thiolate ion for a direct SN2 reaction with the C1 carbon on the farnesyl group.  
This results in formation of a nascent thioether bond to the protein and loss of the 
oxyether bond to the pyrophosphate leaving group, which is stabilized by a Mg2+ ion.  
Pyrophosphate readily leaves the complex first, whereas release of the prenylated protein, 
the rate-limiting step, requires displacement by a new farnesyl diphosphate molecule (76-
78).  
 
DHHC proteins are protein S-acyltransferases 
 DHHC proteins were determined to be the enzymes responsible for cellular S-
acylation through the phenomenal power of yeast genetics.  In 1999, a genetic screen in 
the yeast Saccharomyces cerevisiae using a palmitoylation-dependent RAS2 allele 
revealed the first PAT, effector of ras function, Erf2, and a second protein, Erf4 (79).  
Subsequent studies showed Erf2 function required binding partner Efr4, and they formed 
an endoplasmic reticulum-associated complex (80).  In 2002, the Erf2/Erf4 complex was 
purified and shown to catalyze the transfer of radiolabeled palmitate from CoA to a Ras2-
like substrate, demonstrating it was a bona fide PAT (81).  Concurrently, a second yeast 
protein, Akr1, was also demonstrated to have PAT activity for the substrate Yck2 (82).  
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Analyzing amino acid sequences of these first two PATs lead to the discovery of a larger 
family of proteins called DHHC proteins with a conserved Asp-His-His-Cys cysteine-rich 
domain (DHHC-CRD) (83). 
 DHHC proteins make up a family of enzymes conserved in eukaryotes.  
Searching translated genome databases reveals 7 DHHC proteins in S. cerevisiae, 5 in 
Schizosaccharomyces pombe, 16 in Caenorhabditis elegans, 22 in Drosophila 
melanogaster (84), 23 in Arabidopsis thaliana (85), and 24 in Homo sapiens (86).  In 
mammalian genomes, DHHC genes are designated ZDHHC1- ZDHHC2- ZDHHC3 and 
so on, with the exception that there is no ZDHHC10.  The “Z” reflects the fact that these 
proteins were originally predicted to be zinc-finger proteins involved in protein-protein or 
protein-DNA interactions (87); however, neither the metal nor DNA binding ability of 
these proteins has been characterized. 
 DHHC proteins have several conserved elements, with the function of some 
elements known.  DHHC proteins are named for a highly conserved Asp-His-His-Cys 
motif within a larger cysteine-rich domain of approximately 51 amino acid residues 
(Figure 1.1) (83).  Hydropathy analysis of most DHHC proteins predicts four 
transmembrane domains (TMDs) with the DHHC motif on the cytoplasmic loop between 
TMD2 and TMD3 (27, 88).  Yeast Ark1 and Akr2 and mammalian DHHC17 (HIP14) 
and DHHC13 (HIP14L) are part of a subset of DHHCs predicted to have N-terminal 
ankyrin repeats within the cytoplasm and two additional TMDs.  Indeed, this topology 
was experimentally confirmed for Akr1 (88).  Additionally, homology and phylogenetic 
analysis revealed a conserved DPG (aspartate-proline-glycine) motif N-terminal to the 
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DHHC sequence but within the same cytoplasmic loop and a TTxE (threonine-threonine-
variable-glutamate) motif after the last TMD (Figure 1.1) (83).  The function of these 
motifs is unknown.   
 The C-terminal cytoplasmic tails of DHHC protein vary greatly in sequence and 
length and have been assigned multiple functions.  C-terminal to the TTxE motif, a 16 
amino acid palmitoyltransferase conserved C-terminal (PaCCT) motif was described that 
is conserved in 70% of PATs from eukaryotic organisms (Figure 1.1).  A conserved 
aromatic residue within this motif was essential for yeast DHHC proteins Swf1 and Pfa3 
to S-acylate their protein substrates in vivo (89).  Using mass spectrometry techniques to 
compare human S-acylated proteins in lipid raft versus non-raft membranes, Yang and 
coworkers identified DHHC5, DHHC6, and DHHC8 to be S-acylated on a novel three 
cysteine motif, CCX7-13C(S/T) (20).  For DHHC6, this motif is about 50 residues 
downstream of the PaCCT motif.  Interestingly, for DHHC5 and DHHC8 this tricysteine 
motif overlaps their PaCCT motifs.  The functions of these motifs are largely unknown, 
however one possibility is that acylation-deacylation cycles of the tricysteine motif could 
regulate PaCCT motif accessibility and thus function.  In vivo most long-chain acyl-
CoAs are bound by ACBP (36, 90) and partially purified PAT activity can used ACBP-
bound palmCoA (39).  The PaCCT motif may be involved in recruiting ACBP:acyl-CoA 
complex to the DHHC protein and/or causing the release of acyl-CoA.  It is unknown 
whether DHHC proteins can utilize ACBP-bound acyl-CoAs and the interaction between 
the two is an unexplored area in the field.  The tricysteine and PaCCT motifs are present 
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on DHHCs with different subcellular localizations, arguing against them being 
localization signals.   
 DHHC proteins are localized to multiple membranes throughout the cell.  Ohno 
and coworkers published the localization of ectopically expressed, epitope-tagged human 
and yeast DHHC proteins as well as the tissue expression patterns of human ZDHHC 
mRNAs (27).  The majority of DHHC proteins displayed endoplasmic reticulum (ER) 
and/or Golgi localization.  The exceptions were human DHHC-5, -20, and -21 and yeast 
Pfa5, which were localized to the plasma membrane (PM), and yeast Pfa3, which located 
to the yeast vacuole membrane (27, 91).  However, a number of these results do not agree 
with work from others that looked at endogenous proteins or less highly expressed 
proteins.  For example, Ohno et al described DHHC2 as having very restrictive tissue 
distribution and localizing to the ER and Golgi.  In contrast, another group looking at 
DHHC2 found it was ubiquitously expressed in all tissues (92), and multiple groups have 
found DHHC2 localized to the PM and recycling endosomes (93-96).  Interestingly, 
DHHC2 cycles between endosomes and the PM in PC12 cells and the PM localization is 
dependent on it C-terminal cytoplasmic tail (94).  In neurons, DHHC2 also displays 
regulated localization, translocating from dendritic shaft vesicles to post-synaptic 
densities at the PM of dendritic spines and this translocation is enhanced in response to 
activity blockade (93).  How the localization of most other DHHC proteins is determined 
or regulated remains unknown.  
 DHHC proteins may have other functions in addition to catalyzing protein S-
acylation.  Yeast Swf1, with its DHHC cysteine mutated to alanine, was still able to 
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mediate its functions of organizing the actin cytoskeleton and localizing Cdc42 (97).  
Similar, the Drosophila DHHC protein GABPI (CG17257) has a highly conserved 
DHHC-CRD with the important exception that the DHHC cysteine is a serine (84), which 
in all DHHC proteins tested blocks S-acyltransferase activity (83).  GABPI shows high 
expression in neural tissue and uses its luminal loops, that are on the opposite side of the 
bilayer from the DHHS domain, to bind a Golgi localized glycosyltransferase (98).  The 
mammalian orthologs of GABPI (DHHC-23, -11, and -1) have retained the canonical 
DHHC sequence whereas most insect orthologs have lost it (84, 98), suggesting this 
alternative DHHC function may be unique to insects.  
 DHHC proteins have been implicated in the transport of divalent metal ions.  
DHHC13 shares 69% sequence similarity with DHHC17 and is also referred to as HIP14-
like protein or HIP14L.  These two DHHC proteins have been associated with 
magnesium homeostasis.  Low magnesium concentrations have been shown to increase 
endogenous DHHC-13 and -17 mRNA and protein levels.  When expressed in Xenopus 
oocytes, both DHHC-13 and -17 mediated Mg2+ uptake that was dependent on the DHHC 
cysteine and sensitive to inhibition by 2-BP.  The authors conclude that DHHC-13 and -
17 are Mg2+ transport proteins and DHHC autoacylation regulates transport (99).  Using 
similar techniques, this group also published that DHHC3 (GODZ) is a Ca2+ transport 
protein (100).  While DHHC proteins may have dual functions as both acyltransferases 
and metal ion transporters, a more likely explanation is that DHHC-dependent acylation 
activates metal transporters or transport pathways within the cell.  DHHC proteins have 
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not been directly tested for metal ion transport capabilities, however they are predicted to 
be zinc-binding proteins (87). 
 
Functions and regulation of protein S-acylation  
 Protein S-acylation can cause a variety of effects on the protein that is modified.  
From a technical standpoint, addition of a long-chain fatty acid to a protein increases its 
hydrophobicity, however this can have different functional consequences depending on 
the protein being modified.   
 Serving as a membrane anchor, S-acylation can influence protein localization and 
trafficking.  A biologically important example of this is found on the proto-oncogene H-
ras, which is part of the ras family of genes that are mutated in 30% of all human cancers.  
After prenylation and processing, H-ras is either mono- or dually acylated at cysteines 
181 and 184.  Monoacylation at Cys181 is required and sufficient for efficient trafficking 
to the plasma membrane.  In contrast, monoacylation at Cys184 results in trafficking to 
the Golgi but not beyond (101, 102).  A second example is the ATP-binding cassette 
transporter (ABC)A1 that is acylated on four cysteine residues, likely by DHHC8.  
Mutation of any one of these sites prevents ABCA1 trafficking to the plasma membrane 
(103). 
 The membrane microdomain distribution of a protein can also be influence by S-
acylation.  A-Kinase anchoring protein 79 (AKAP79) is S-acylated on two N-terminal 
cysteine residues and is involved in the clustering of proteins for efficient cyclic AMP 
signaling.  Mutation of AKAP79’s acylation sites excludes it from lipid rafts and thus 
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prevents it from regulating adenylyl cyclase type 8 (AC8) activity (104).  Acylation of 
the death receptor Fas on a cytoplasmic cysteine residue adjacent its single TMD targets 
it to cytoskeleton-linked lipid rafts.  The Fas receptor ligand, FasL, is similarly acylated 
and localizes to rafts.  Acylation of both receptor and ligand is necessary for Fas-FasL 
complex assembly in rafts and signaling to downstream caspases (105, 106).  Acylation 
was shown to promote raft affinity for 35% of raft-associated transmembrane proteins 
(107).  However, not all S-acylated transmembrane proteins associate with rafts, one 
example being transferrin receptor 1 (108).  Other examples include the anthrax toxin 
receptors, TEM8 and CMG2.  S-acylation of these transmembrane proteins prevents their 
association with lipid rafts, which in turn prevents premature ubiquitination by Cbl3, a 
necessary step in toxin internalization (109). 
 Protein S-acylation can regulate protein-protein interaction and facilitate complex 
formation.  Two examples of this already mentioned are AKAP79-AC8 and Fas-FasL.   
A third example is Gαo, which when lacking an acyl-group exists as a mixture of 
monomers and oligomers (dimers, trimers, tetramers, and pentamers) that disaggregate 
into monomers after GTPγS stimulation.  Acylated Gαo however, exist only as oligomers 
and is resistant to GTPγS-dependent disassembly (110).  In the case of huntingtin (htt), S-
acylation by DHHC17 (HIP14) reduces its ability to aggregate and form inclusion (111).  
 Finally, regulation of enzyme activity has been credited as a function of protein S-
acylation.  Acylation of G-protein-coupled receptor kinase GRK6 has dual roles in 
increasing its activity.  Acylation promotes membrane association of GRK6, bringing it 
closer to its membrane-bound substrates and acylation also increases the kinase catalytic 
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activity of GRK6 (112).  Within the epithelial Na+ channel (ENaC), which has several 
transmembrane domains, S-acylation regulates channel gating (113).   
 Given the multiple functions of protein S-acylation and the fact that its thioester 
bond is reversible, it is likely that DHHC-mediated S-acylation is regulated in cells.  To 
date the only process known to regulation DHHC protein activity is interaction with 
binding partners.  Both yeast Erf2 and its human ortholog DHHC9 require interaction 
with accessory proteins Erf4 and GCP16, respectively, for transfer and autoacylation 
activities (81, 114) (Also see appendix).  Perhaps serving a similar role, huntingin (htt) 
was shown to bind DHHC17 (HIP14) and stimulate both DHHC autoacylation and 
acylation of multiple substrates (115).   
 An alternative mechanism of regulating protein S-acylation is to control the 
access of DHHC proteins to cysteine thiols on protein substrates.  Phosphodiesterase 10A 
(PDE10A) is phosphorylated in Thr16 and this prevents acylation of Cys11, which is 
otherwise acylated by DHHC7 and/or DHHC19 (116).  Recently, the reciprocal 
modification of cysteine residues 3 and 5 in postsynaptic density protein 95 (PSD-95) has 
been described (117).  Protein S-nitrosylation at these sites reduced S-acylation and vice 
versa.  An alterative way to control DHHC access to substrate thiols is to regulate DHHC 
protein localization.  This is the case for DHHC2, which following activity blockade in 
neurons, translocates between intracellular vesicles and postsynaptic densities where it 
mediates acylation of PSD-95 (93, 94).  To date, there are no known posttranslational 
modifications of DHHC proteins that regulate acyltransferase activity.  
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Biological importance of DHHC proteins in disease 
 As our understanding of DHHC proteins increases, a growing number of human 
diseases are being associated with DHHC proteins and protein S-acylation.  ZDHHC 
genes that have been associated with disease are summarized in Table 1.1.  A table 
summarizing DHHC proteins and their known protein substrates has recently been 
published (86).  Several of these mammalian S-acylated proteins also have disease 
connections.  Finally, the S-acylation of a large number of viral and parasitic proteins has 
been reported and in many cases, protein S-acylation is necessary for efficient infection 
(118-120).  A few diseases connections to DHHC proteins are highlighted below; one is 
referred to recent reviews for more examples (86).  
 As previously mentioned, the causative protein of Huntington disease (HD), 
huntingtin (htt) is an S-acylated protein.  DHHC17, also called huntingtin interacting 
protein 14 (HIP14), has been implicated as the PAT for htt.  Polyglutamine tract 
expansion of htt, which proportionally increases susceptibility to HD, reduces interaction 
with DHHC17 and consequently reduces htt acylation.  Nonacylated htt forms inclusions 
faster and is more toxic than acylated htt (111, 121).  DHHC17 is also a potential 
oncogene having the ability to induce colony formation and anchorage-independent 
growth in cell lines, and tumors in mice (122).   
 Several DHHC proteins have been associated with human cancer.  ZDHHC2 was 
originally identified as a gene on 8p21.3-22 that displayed reduced expression associated 
with metastasis (REAM), suggesting that ZDHHC2 might be a tumor suppressor.  
Reduced expression was observed in more than half of the human colorectal cancers 
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examined and somatic mutations of ZDHHC2 were found in colorectal cancer (M356I, 
Figure 1.1), hepatocellular carcinoma (S306F), and a nonsmall lung cancer (R269stop) 
(92).  Interestingly, two of these mutations (M356I and S306F) are found within a region 
of the C-terminal tail of DHHC2 (N299 to the C-terminus) that controls its dynamic 
translocation between recycling endosomes and the plasma membrane (94).  
 
Concluding Remarks   
 In my thesis work, I have focused on developing a better mechanistic 
understanding of how DHHC proteins catalyze protein S-acylation.  Information on a 
protein’s catalytic mechanism can provide insight into the function of residues within an 
active site and clarify structure-function relationships.  Kinetic rate constants predict how 
enzyme activity will respond to cellular changes in substrate availability and provide 
insight into rate-limiting steps within pathways.  Kinetic parameters can be used to 
quantify enzyme preferences among competing substrates or to quantify different 
enzymes preferences for the same substrate.  Knowledge of substrate addition and 
product release can be beneficial in the development of enzyme inhibitors.  Inhibitor 
sensitivities and mechanisms can reveal information about an enzyme’s active site and 
catalytic mechanism.  By initiating these types of studies on DHHC proteins, I sought to 
reveal new information about this biologically important family of enzymes.  
 In the following chapters I discuss the biochemical and enzymatic 
characterization of DHHC proteins and potential DHHC inhibitors.  When these 
investigations began, partial purification and limited PAT activity assessment had only 
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been described for a few DHHC proteins (81, 82, 114, 123).  In Chapter 2, I described the 
improvement of methods and assays to purified and characterize DHHC proteins.  These 
procedures were used to determine that DHHC proteins use a two-step ping-pong 
catalytic mechanism.  Additionally in Chapter 3 is the first reported evidence that DHHC 
proteins display acyl-CoA specificity.  Assays that I developed were also used to 
characterize known and potential inhibitors of DHHC proteins.  In the final chapter I 
discuss the implication of these studies and potential future studies based on these results.  
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Table 1.2.  Proteins modified by S-acylation with acyl length other than 16-carbon 
palmitate 
Fatty Acid1 Proteins References 
14:0 band 3 (AE1), rhodopsin (31, 124) 
15:0 rhodopsin (31) 
16:1 band 3 (AE1), rhodopsin, unidentified proteins (31, 124, 125) 
18:0 P-selectin, HEF (influenza C virus), E1 (Semliki 
Forest virus), band 3 (AE1), rhodopsin 
(31, 124, 126, 127) 
18:1 band 3 (AE1), rhodopsin (31, 124) 
18:2 rhodopsin (31) 
20:4 G-protein α-subunits i, q, and z; rhodopsin, 
unidentified platelet proteins 
(31, 128, 129) 
20:5 unidentified platelet proteins (129) 
22:6 rhodopsin (31) 
Notes:  1Number of carbons in acyl chain and number of desaturations.
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Table 1.3.  DHHC proteins associated with disease 
DHHC1 Disease Ref. 
2 (REAM) Cancer: colorectal, hepatocellular, and lung (92) 
3 (GODZ) Squamous cell cervical carcinoma (130) 
5 Drip loss (in pigs) (131) 
7 (SERZ-β) Invasive breast cancer, oestrogen receptor-positive (132) 
8 Radiation susceptibility (133) 
8 Schizophrenia2 (134, 135) 
8 Smooth pursuit eye movement (SPEM) abnormality (136) 
8 DiGeorge syndrome (22q11.2 deletion syndrome) (137, 138) 
9 X-linked mental retardation associated with Marfanoid habitus (139) 
9 Microsatellite stable and instable colorectal cancer (140) 
9 Splay leg (in pigs) (141) 
9 (CGI-89) Colorectal cancer (142) 
11 Bladder cancer progression (143) 
11 Cancer: non-small lung (144) 
13 (HIP14L) Alopecia, osteoporosis, systemic amyloidosis (145) 
14 Post-transplant lymphoproliferative disorders 
Diffuse large B-cell lymphomas 
(146) 
14 Cancer: gastric  (147) 
14 Acute biphenotypic leukemia 
Acute myeloid leukemia 
(148) 
15 X-linked mental retardation (149) 
17 (HIP14) Huntington’s Disease (150) 
17 Diabetes (151) 
17 Cancer: colon, stomach, breast, lung, and liver (152) 
19 Enterotoxigenic E. coli F4ab/ac susceptibility (in pigs) (153) 
20 Cancer: ovarian, breast, and prostate (154) 
21 Hair loss  (155) 
Notes:  1Alternative names for DHHC proteins are given in parenthesis.2Multiple reports 
have been published both supporting and refuting the association between ZDHHC8 and 
schizophrenia.    
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Figure 1.1.  DHHC consensus motif and predicted topology of human DHHC2.  
A, Consensus sequence for the DHHC cysteine-rich domain (CRD) and surrounding 
DPG and TTxE motifs.  B, DHHC2 (367 amino acids) is predicted to have four 
transmembrane domains as indicated here.  Highlighted are the DPG (purple), DHHC 
(red), and TTxE (cyan) motifs and the seven conserved cysteine residues of the 
DHHC-CRD (yellow).  In addition, DHHC2 has a PaCCT motif (orange).  The 
C-terminal tail of DHHC2 (gray, residues 299-367) is involved in regulating DHHC2 
localization in cells.  Somatic mutations (green) have been found in lung (R269stop), 
heptaocellular (S306F), and colorectal (M356I) tumors.
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Chapter 2 
 
 
 
 
 
 
 
 
 
Development of Assays to Monitor  
DHHC-mediated Protein S-acylation  
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Abstract 
 To facilitate our understanding of DHHC-mediated protein S-acylation, new and 
well-characterized experimental assays were needed.  DHHC proteins are integral 
membrane enzymes and thus require detergent for membrane extraction and purification.  
However, detergents as well as other assay components can affect enzyme behavior.  The 
conditions for an assay of protein S-acylation was modified from published protocols to 
optimize enzyme activity.  The assay is referred to as the standard PAT assay, which 
measures the transfer of radiolabeled palmitate from palmitoyl-CoA to protein substrate.  
Improving this assay has revealed important aspects of DHHC function and enabled more 
detailed studies into the mechanism of DHHC proteins.  
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Introduction 
 Developing purification protocols and robust and well-characterized assays for 
enzyme function are critical first steps to mechanistically studying an enzyme.  Using the 
reductionist’s approach to studying enzymes allows one to minimize the myriad of other 
simultaneous cellular processes and focus on the reaction of interest.  Reconstitution of 
enzyme function with purified components allows measurement of activity with minimal 
side reactions and is a staple of the biochemist’s toolbox.  Here, I developed and 
improved assays for the reconstitution of DHHC PAT activity with purified components.  
 Earlier groups attempting to purify and identify PATs developed an assay for 
tracking PAT activity.  These groups applied detergent extracts from liver or brain 
membranes to conventional chromatography columns.  Column fractions were incubated 
with radiolabeled palmCoA and a protein substrate capable of being S-acylated.  
Reactions were stopped, resolved by SDS-PAGE, and analyzed by both fluorography, 
indicating which bands incorporated radiolabel palmitate, and scintillation counting, 
which provided a quantitative measure of PAT activity.  
 Once DHHC proteins were identified as catalyzing protein S-acylation, 
recombinant protein technologies could be used to enrich PAT activity.  Affinity-tagged 
mammalian DHHC proteins were expressed with the Baculovirus system in Sf9 cells and 
purified over sequential nickel and FLAG affinity resins.  When I joined the lab, the 
resulting purified DHHC proteins were tested with the same PAT assay used to monitor 
activity extracted from tissue even though this assay had not been optimized for DHHC 
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PAT activity.  By carefully evaluating DHHC activity under various reaction conditions, 
I made several improvements to our standard radiolabel-based PAT assay.  
 
Results and Discussion 
 Purification of DHHC proteins and PAT assay reagents—My studies have 
focused primarily on DHHC2 and DHHC3, requiring protocols to express and purify 
both enzymes, as well as their protein substrates.  Early studies with a His6-Express-
DHHC2 (pML850) construct showed that the enzyme was undergoing C-terminal 
proteolysis, with enzyme autoacylation displaying two bands on films.  Furthermore, one 
of the enzyme bands comigrated with the substrate myrGαi1.  Thus a construct was 
generated with affinity tags at both termini and the calmodulin binding peptide, His6-
Express-CBP-DHHC2-FLAG-His6 (pML943), to both limit proteolysis and increase the 
molecular weight.  I first attempted to purify pML943 using sequential nickel and 
calmodulin resins.  Unfortunately buffers used to elute from calmodulin resin are 
incompatible with binding to nickel resin and vice versa.  This oversight was not unique 
(156) and a review now warns about using a His6-CBP tandem affinity tag (157).  
However, sequential chromatography using nickel and FLAG-peptide affinity columns 
resulted in relatively pure protein that immunoreacted with Express (Chapter 4, Figure 
4.2) and Flag antibodies (not shown), suggesting that full-length protein was purified.  
Mouse DHHC3-FLAG-His6 was purified in a similar way.  Detailed methods for 
purification of DHHC2 and DHHC3 are found in chapters 4 and 3, respectively. 
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 I used two N-myristoylated proteins as protein substrates for DHHC2 and 
DHHC3, N-myristoylated Gαi1 (myrGαi1) and N-myristoylated lymphocyte specific 
kinase, N-terminal residues 1-226 (myrLckNT).  These were generated in E. coli 
coexpressing N-myristoyltransferase and were purified as described in Chapters 3 and 4.  
The lipid substrate in the PAT assay is [3H]palmCoA,  I observed a spurious band in 
films of PAT assays that appeared at a position near DHHC2.  This was identified as 
residual acyl-CoA ligase from the palmCoA preparations.  To remove this contaminant, a 
chloroform-methanol extraction step was added to the palmCoA purification protocol.  
 Radiolabel-based PAT assay optimization—A protocol for assaying PAT activity 
from cell lines and tissues had previously been published by our group (Table 2.1, left 
side) (114), however reaction conditions had not been tested for their effect on DHHC 
activity.  Detergents needed for the purification of integral membrane proteins can have 
unwanted effects on enzyme activity and behavior (158, 159).  Initially our lab used 
Triton X-100 for enriching and assaying an unknown PAT activity (26).  Because DHHC 
proteins were extracted from membranes and purified with nonionic n-dodecyl-β-D-
maltoside (DDM), we sought to test DHHC PAT activity in the presence of DDM.  As 
shown in Figure 2.1A, DHHC2 acylates myrGαi1 to a much higher extent when DDM 
detergent is used versus Triton X-100.  This is consistent with other reports of integral 
membrane proteins showing highest activity in DDM when tested against a panel of 
detergents (160).  Dose-response curves were performed at various DDM concentrations 
(Figure 2.1B).  The highest activity was seen at 0.01% DDM, which is similar to DDM’s 
critical micelle concentration (CMC) of 0.009% in water (ThermoScientific).  Lower 
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DDM concentrations likely resulted in loss of micelles and DHHC aggregation, whereas 
high DDM concentrations likely resulted in more empty micelles, which could still bind 
substrates and sequestered them from micelles containing DHHC proteins.  
 Because DHHC proteins are predicted to be zinc-binding proteins, the buffer 
component EDTA was tested, however no effect was observed even at the highest 
concentration (Figure 2.1C).  Interestingly when zinc ions were included in the assay, 
DHHC2 incorporated less palmitate into myrLckNT relative to either water or magnesium 
ion controls (Figure 2.1D).  It is known that the N-terminal SH3 domain of Lck has a Kd 
for zinc of less than 100 nM and that zinc binding induces Lck homodimerization (161), 
but it is unknown whether zinc binding or dimerization alter Lck’s ability to be acylated.  
Additionally, zinc also likely affected DHHC2 because enzyme autoacylation was 
observed on film in samples containing magnesium but not zinc (data not shown).  
Investigations with the yeast PAT Erf2/Efr4 suggest that zinc concentrations as low as 20 
µM are inhibitory (Robert Deschenes, personal communication).  Whether DHHC 
proteins bind zinc as predicted remains unknown and warrants further investigation.  
 Thiol-based reducing agents—Protein S-ayclation occurs through a thioester 
linkage that is reversible.  While this property is beneficial to cells, using 
acylation/deacylation cycles to regulate protein behavior, it presents challenges to the 
researcher.  The thioester bond is susceptible to cleavage by reducing agents and their 
concentration needs to be kept to a minimum.  Conversely, formation of a thioester bond 
requires free cysteine residues that are prone to oxidation.  Thus early PAT assays 
included low levels of dithiothreitol (DTT) in all buffers to maintain this balance (Table 
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2.1, left side).  This practice was questioned when initial attempts to purify autoacylated 
enzyme for single turnover pulse-chase assays were unsuccessful.  DHHC protein was 
pre-incubated with low concentrations of [3H]palmCoA, forming a radiolabeled acyl-
DHHC.  High concentrations of unlabeled palmCoA were added with or without a 
protein substrate and aliquots removed during a time course.  It was predicted that [3H]-
palmitate would only transfer off the DHHC when protein substrate was present.  
However, even in the absence of a protein substrate, DHHC proteins lost their 
radiolabeled palmitate on a rapid time scale (data not shown [PAT ID#525]).  This 
suggested that DHHC proteins were rapidly acylating and deacylating during a standard 
PAT assay and thus hydrolyzing and depleting palmCoA pools.  
 The hypothesis that DHHC proteins were hydrolyzing palmCoA in the presence 
of thiol-based reducing agents was tested.  DHHC3 was incubated with standard buffers 
containing 1 mM DTT for either 0.2 or 30 min.  The reaction was stopped and analyzed 
by thin layer chromatography (TLC) for production of free [3H]-palmitate and by SDS-
PAGE gels and fluorography for enzyme autoacylation (Figure 2.2A).  As shown, after 
30 min DHHC3 produced more free [3H]-palmitate than a catalytically inactive DHHS2 
or buffer control.  Also consistent with the hydrolysis model, DHHC3 at 30 min was 
radiolabeled less than at the earlier time point suggesting its palmitate was being released.  
To determine whether the hydrolysis of palmCoA was reducing-agent dependent, time 
courses for free [3H]-palmitate production were performed with or without DTT or β-
mercaptoethanol (β-ME) and monitored by TLC.  For both DHHC2 and DHHC3, 
reactions with reducing agent produced more [3H]-palmitate than those without (data not 
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shown [PAT ID#533, 547, 629]).  DHHC enzyme autoacylation was also studied in the 
presence of reducing agents.  As shown in Figure 2.2B, less acyl-DHHC3 was formed 
when DTT or β-ME were included in the assay.  Additionally, the amount of autacylated 
DHHC3 rapidly decreased with time in the continued presence of reducing agent and 
palmCoA.  A similar but less pronounced pattern was also seen with DHHC2 (Figure 
2.2C).  This rapid decrease in acyl-DHHC and the production of free [3H]-palmitate 
suggest that DHHC proteins were autoacylating and then deacylating in a reducing agent-
dependent process.  Deacylation could occur by either an acyl-DHHC transferring its 
palmitate to a free thiol present on the reducing agent or by the reducing agent cleaving 
the acyl-enzyme thioester bond.  Given the ratio of reducing equivalents to palmCoA of 
2000 to 1, there is ample reducing agent present to greatly deplete the palmCoA pool.  
This is suggested by DHHC3 deacylating to a low steady state level (Figure 2.2B).  The 
time frame required to reach this steady state level (under 10 min) was similar to the 
linear reaction range observed in substrate acylation time courses (not shown).  One 
possibility is that the linear reaction ranges of substrate acylation were shortened because 
palmCoA pools were being rapidly depleted.  Indeed, when reducing agent was omitted 
from a time course PAT assay with DHHC2 and myrLckNT, the linear range was 
extended to at least 30 min [PAT ID#553].  Measuring acylation within the linear 
reaction range was critical for the inhibitor and kinetics studies in subsequent chapters.  
The effect of DTT on substrate S-acylation was also measured (Figure 2.2D).  As 
predicted, DHHC2 transferred less palmitate to myrLckNT in the presence of DTT.  
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 Given the negative effect of thiol-based reducing agents on DHHC PAT activity, I 
sought to determine if reducing agents could be omitted.  Reducing agents were 
originally included in PAT assays to maintain free thiols available for acylation.  High 
pH accelerates non-enzymatic acylation and was used to evaluate the availability of thiols 
on myrLckNT in the presence of reducing agents.  Figure 2.2E shows that treatment with 
reducing agents resulted in more myrLckNT being acylated at high pH.  This suggests that 
reducing agents are needed for maintaining free thiols on protein substrates.   
 Replacing thiol-based reducing agents with TCEP—The non-thiol based reducing 
agent tris(2-carboxyethyl)phosphine (TCEP) was evaluated and determined to be less 
detrimental for PAT assays than DTT.  TCEP is a phosphine-based reducant that unlike 
DTT is non-volatile, odorless, resistant to air oxidation, and compatible with immobilized 
nickel affinity capture resins (Thermo Scientific) (162).  TCEP was tested in a DHHC2 
autoacylation PAT and shown to increase incorporation of palmitate into DHHC2 but not 
the DHHS2 control (Figure 2.2 C).  Analyzing reactions from the same assay by TLC 
also showed that inclusion of TCEP produced considerably less free [3H]-palmitate than 
inclusion of DTT (data not shown [PAT ID#629]).  This suggests TCEP does not cause 
the DHHC-catalyzed acyl-CoA hydrolysis that was observed with DTT and β-ME.  
TCEP was also tested and shown to maintain free thiol availability on a protein substrate 
at similar levels to DTT (Figure 2.2E).  Including TCEP in a PAT assay with DHHC2 
and myrLckNT resulted in a 4-fold increase in palmitoyl-myrLckNT versus a reaction 
lacking reducing agent (Figure 2.2F).  This indicated that TCEP could maintain free 
substrate thiols while not negatively affecting DHHC2 PAT activity.  A titration of TCEP 
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into an assay with DHHC3 and myrGαi1 was carried out to determine the optimal TCEP 
concentration.  Figure 2.2G indicates that for this enzyme-substrate pair, concentrations 
of TCEP greater than 1 mM were inhibitory to palmitate labeling of myrGαi1.  For this 
enzyme-substrate pair inclusion of TCEP into this assay did not increase substrate 
acylation over a reaction lacking reducing agent, which is unlike the DHHC2-myrLckNT 
pair in Figure 2.2F.   
 Together these results support the replacement of DTT with TCEP in PAT assays.  
Given that reducant is included to maintain substrate thiols (Figure 2.2E) and that high 
TCEP concentrations are inhibitory (Figure 2.2G), it is recommended that 1 mM TCEP 
only be included in the substrate buffer as shown in Table 2.1.  This allows reduction of 
substrate thiols as well as dilution of the TCEP when the remaining assay components are 
added.  Although unlikely, one possibility that was not investigated is that TCEP may 
break physiologically relevant disulfide bonds and the newly exposed thiols become sites 
of acylation.  This could be tested by determining if TCEP causes acylation of a substrate 
that has the in vivo modified cysteine residues mutated (e.g. myrLckNT C3S C5S or 
myrGαi1 C3S).  Finally, the difference in response to TCEP between DHHC2 and 
DHHC3 may suggest that DHHC proteins respond differently to reducing agents.    
 Effect of various compounds on DHHC-mediated PAT activity—Several other 
compounds were tested in the radiolabel-based PAT assay as summarized in Table 2.2 
and are briefly discussed here.  During the purification of DHHC proteins several 
protease inhibitors are used to limit protein degradation.  These compounds were tested 
for their effect on DHHC activity and most were found to have no effect.  Because 
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inhibitor compounds tend not be soluble in water at high concentrations and are instead 
dissolved in organic solvents, these solvents were tested.  Of these, ethanol showed 
strong inhibition of PAT activity consistent with work by others in cells showing that 
ethanol inhibits palmitoylation of G-protein α-subunits (163).  Dimethylsulfoxide 
(DMSO) displayed the least inhibition of the solvents tested and was used as the vehicle 
for additives to the assay.  Multiple reports have described the use of cerulenin, 
tunicamycin, and analogs of each to inhibit protein acylation within cells (164-167).  
Neither cerulenin nor tunicamycin inhibited DHHC2 PAT activity when tested, 
suggesting that in cells these compounds may have other targets such as acyl-CoA ligase 
or enzyme involved in fatty acid synthesis.  Given the high conservation of cysteine 
residues within the DHHC cysteine rich domain and thus their likely importance to 
enzyme function, it was not surprising that the cysteine-specific alkylating reagent N-
ethylmaleimide (NEM) strongly inhibited DHHC activity.  Interestingly, the histidine-
specific alkylating reagent diethylpyrocarbonate (DEPC) also inhibited DHHC activity.  
This may point to the histidine residues of the DHHC motif playing an important role in 
acyltransfer.   
 Finally, two compounds currently in clinical trials were tested for ability to alter 
DHHC PAT activity.  Tecovirimat (ST-246) prevents the function of p37 (F13L), a 
palmitoylated protein necessary for poxvirus infections and has shown promise as an 
orally active drug (168, 169).  When tested in our assay it showed no effect on PAT 
activity.  Farnesyl thiosalicylic acid (FTS, Salirasib), which was originally identified as 
inhibiting carboxymethylation of CaaX motifs (170, 171), showed dose-dependent 
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inhibition of both DHHC2 and DHHC9.  One-possibility is that the long hydrophobic 
farnesyl-side chain of this inhibitor competes with the acyl-chain of palmCoA for binding 
to the DHHC.  How DHHC proteins recognize and differentiate lipid substrates is 
unclear.  
 
Concluding remarks and future experiments 
 DHHC acyltransferase activity could be further improved by investigating other 
conditions.  We used detergent to extract and purify DHHC proteins within detergent 
micelles, however in cells, DHHC proteins are found within a phospholipid bilayer.  
Thus, reconstitution of DHHC proteins into liposomes may better represent physiological 
conditions.  For other integral membrane enzymes, profound effects on kinetics and 
specificity have been described following reconstitution into lipid vesicles.  For example, 
the yeast polytopic integral membrane Ste14p, which acts on Ras, displays a ~15-fold 
enhancement upon reconstitution into E.coli liposomes (160).  Another integral 
membrane enzyme MGAT (monoacylglycerol acyltransferase) displays 11-fold 
stimulation by reconstitution into phosphatidic acid containing micelles, but inhibition by 
oleate and sphingosine containing vesicles (172).  One caveat of reconstitution into the 
liposomes is orientation of the DHHC protein within the lipid bilayer.  It is likely that 
some DHHC proteins would incorporate with their active site to the lumen of the 
liposome and thus, inaccessible for interaction with either substrate during a PAT assay.  
When determining enzyme activity, these effectively inactive DHHC proteins could skew 
calculations of turnover and specific activity.   
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 An alternative method of lipid reconstitution that gets around the orientation 
problem of liposomes is the use of high-density lipoprotein particles, also called 
Nanodiscs.  Nanodiscs consist of a lipid bilayer approximately 7 nm in diameter 
surrounded by a self-assembling membrane scaffolding protein (MSP) ‘belt’ derived 
from human apolipoprotein A-1 (apo A1).  Various lipids, including cholesterol, can be 
used to form the bilayer and MSP mutants of varying length can alter the bilayer diameter 
(173).  Nanodisc components and a membrane protein of interest purified in detergent are 
mixed and as the detergent is removed, membranes proteins incorporate into the 
Nanodisc lipid bilayer.  One advantage of this system is that both sides of the bilayer are 
solvent accessible, and thus, protein orientation within the bilayer is not an issue.  The 
contribution of the surrounding lipid environment to DHHC activity is a largely 
unexplored area.  
 For my studies DHHC proteins were epitope tagged at the N-terminus (DHHC2 
pML850), the C-terminus (DHHC3), or both (DHHC2 pML943) with multiple different 
tags.  The yeast DHHC protein Erf2 displayed ~30% lower autoacylation and ~50% 
reduced transfer activity when FLAG-tagged at the C-terminus versus the N-terminus 
(83).  Erf2-FLAG reduced activity could result from loss of interaction with its binding 
partner Erf4, however this was not tested.  Nevertheless, given this precedent, the 
placement of affinity purification tags on DHHC proteins should be investigated.   
 As we learned more about DHHC proteins, differences are being found among 
family members.  These include differences in acyl-CoA specificities (Figures 3.3-5), 
TCEP-induced activity enhancement (Figures 2.2F and G), binding partner requirements, 
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and protein substrate preferences.  Thus, the idea that one set of assay conditions be 
optimal for all DHHC proteins seems unlikely and DHHC-specific protocol 
modifications may be needed.  For other enzymes families that have been well 
characterized, assay conditions differ from one isoform to another.  For example, within 
the PKC family of protein kinases, differences are noted in calcium, magnesium, 
diacylglycerol, and phospholipid requirements for maximal activity (174).  
 Given the data presented here regarding the use of thiol-based reducing agents in 
PAT assays, care should be taken in analyzing previously published results.  One 
example is the inhibitor studies presented in Chapter 4 of this work.  These studies were 
carried out before we knew about the detrimental effects of DTT on DHHC-mediated 
PAT activity.  It is possible that those compounds that failed to inhibit DHHC proteins as 
expected did so because of the presence of DTT within reaction buffers.  If inhibitors 
reacted with thiols within the DHHC protein, it is feasible the DTT could have removed 
these inhibitors and restored enzyme activity.  To determine if DTT affected inhibitor 
action, DHHC9 was analyzed with the inhibitors in the absence of reducing agent.  No 
change was observed in the inhibition profile (data not shown [PAT ID#561]).   
 A second example where DTT may have affected enzyme activity is the work 
presented by Mitchell and coworkers with the yeast DHHC protein Erf2 (175).  They 
developed a continuous assay to monitor palmCoA use by coupling the release of CoA to 
the reduction of NAD+ to NADH by α-ketoglutarate dehydrogenase and monitoring the 
change in NADH fluorescence.  Using this assay they measured the rates of palmCoA 
hydrolysis by wildtype and several mutants of Erf2.  The buffers for this assay were 
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reported to contain 1 mM DTT.  If Erf2-catalyzed hydrolysis of palmCoA is DTT-
dependent as shown here for other DHHC proteins, then their reported hydrolysis rates 
were likely dependent on reducing agent abundance and higher than rates had DTT been 
omitted or TCEP used.  While this would not change the major findings of the paper, it 
complicates comparison of palmCoA hydrolysis rate to those determined by others.   
 Having robust, well-characterized assays of enzyme activity is one of the first 
steps in biochemically investigating an enzyme.  Here I described the optimization and 
characterization of a number of properties for the radiolabel-based PAT assay.  This 
characterization was necessary for subsequent inhibitor studies, which needed to be 
performed within the linear reaction range.  Likewise, the single turnover assays used to 
determine the kinetic mechanism of DHHC proteins required purification of the acyl-
DHHC transfer intermediate that was not possible until DTT was omitted from buffers. 
Together, these optimization experiments have improved the main assay used to study 
DHHC function and have opened the door for new investigations. 
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Table 2.1 Standard radiolabel-based PAT assay 
Fall 2005 (114) Current Conditions 
10 µL Enzyme in TEDT Buffer 
 50 mM Tris pH 7.4 
 125 mM NaCl  
 1 mM EDTA 
 10% glycerol 
 0.1% Triton X-100 
 1 mM DTT 
 
10 µL Enzyme in Enzyme Dilution Buffer 
 50 mM MES pH 6.4 
 100 mM NaCl 
 1 mM EDTA 
 10% glycerol  
 0.1% DDM 
10 µL Substrate in HED 
 20 mM HEPES pH 8.0 
 1 mM EDTA 
 1 mM DTT 
 
10 µL Substrate in MET 
 50 mM MES pH 6.4 
 1 mM EDTA 
 1 mM TCEP 
 
30 µL Reaction Hot Mix 
 167 mM MES 6.4 
 1 mM DTT 
 1.7 µM [3H]-palmitoyl-CoA 
 
30 µL Reaction Hot Mix 
 50 mM MES pH 6.4 
 1.7 µM [3H]-palmitoyl-CoA 
 
Reaction at 30°C and stop with  
5X Sample Buffer + 5 mM DTT final  
Heated 100°C for 60 sec 
Reaction at 25°C and stop with  
5X Sample Buffer + 2 mM TCEP final  
Heated 55°C for 60 sec 
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 Table 2.2 Effect of various compounds on PAT activity5  
PAT
ID# 
Compound 
Conc. 
Percent 
Inhibition 
DHHC 
(pML) Sub. 
729 Zinc (Zn2+) 2 – 20 mM2 100 2 (943) myrLckNT 
729 Magnesium (Mg2+) 2 – 20 mM2 0 2 (943) myrLckNT 
179 3X FLAG ® peptide 3 – 333 ng/µL1 0 2 (943) myrGαi1 
263 Roche Complete® EDTA-free inhibitor tablets 
1 tablet per 32 
mL1 0 2 (943) myrLckNT 
263 Pepstatin A 5 µg/mL1 0 2 (943) myrLckNT 
123 N-α-Tosyl-L-lysinyl-chloromethylketone (TLCK) 0.5 – 10 mM
2 0 to 26  2 (850) myrGαi1 
123 N-tosyl-L-phenylalaninyl-chloromethylketone (TPCK) 0.5 – 4 mM
2 0 2 (850) myrGαi1 
123 Phenylmethanesulfonylfluoride (PMSF) in 2-Propanol 0.2 – 1 mM
2 −226 2 (850) myrGαi1 
123 2-Propanol 2%2 −116 2 (850) myrGαi1 
181 Ethanol (EtOH) 10%1 87 2 (943) myrGαi1 
123 Methanol 2%2 0 2 (850) myrGαi1 
289 Dimethyl sulfoxide (DMSO) 0 – 50%
1 
0 – 50%1 
Inhibits at >20% 
Inhibits at >10% 
2 (943) 
2 (943) 
myrGαi1 
myrLckNT 
175 
181 Tunicamycin 
1 – 100 µM2 
5 – 500 µM1 0 2 (943) myrGαi1 
175 Cerulenin 1 – 1000 µM2 0 2 (943) myrGαi1 
117 
119 Palmitic Acid (PA) 
50 – 
5000 µM1 0 to 14  2 (850) myrGαi1 
63 Diethylpyrocarbonate (DEPC) 5 mM1 59 2 (850) myrGαi1 
63 N-Ethylmaleimide (NEM) 5 mM1 88 2 (850) myrGαi1 
289 Tecovirimat (ST-246)3 0.5 – 500 µM2 0 2 (943) myrGαi1 myrLckNT 
427 Farnesyl Thiosalicylic Acid (FTS, Salirasib)4 
5 – 1580 µM1 
1580 µM1 
0 – 100 
100 
2 (943) 
9 (418) 
myrLckNT 
H-ras 
Notes: 1Concentration during pre-incubation with DHHC before addition of substrates. 
2Final concentration in assay, no pre-incubation.  
3Prevents function of p37 (F13L), a palmitoylated protein required by poxvirus (168, 169). 
4Inhibits carboxymethylation of CaaX motifs (171).  
5The concentrations of reaction components varied.  Typical ranges were DHHC protein, 2 to 20 
nM; protein substrates myrGαi1, myrLckNT, or H-ras 0.5 to 2 µM; and [3H]palmCoA, 0.5 to 1.3 
µM.  Reactions were incubated at 25°C for 4 to 12 min.6These compounds stimulated DHHC 
activity.  
6These compounds stimulated DHHC activity.   
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Figure 2.1.  Detergent and buffer effects on in vitro DHHC PAT activity.  A, DHHC2 (pML850) was 
assay with myrGαi1 in the presence of either 0.02% Triton X-100 or 0.02% n-dodecyl-β-maltoside (DDM) 
[PAT ID#107; n=1].   B, DHHC3 (1000 fmol) autoacylating in various amounts of DDM detergent for 2 min 
on ice in 1 μM [3H]palmCoA [PAT ID#531; n=2].  C, E, and F, DHHC3 (500 fmol) autoacylating in EDTA, 
glycerol, or NaCl at the inducated concentrations for 4 min at 25°C in 1 μM [3H]palmCoA [PAT ID#601; 
n=1].  D, DHHC2 (5 nM, pML943) was assayed for the ability to acylate myrLckNT (1 μM) in the presence 
of either ZnCl2 or MgCl2 for 6 min at 25°C in 1.2 μM [3H]palmCoA. The final concentration of metal ions 
in the 50 μL reaction is listed  [PAT ID#729; n=1].
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FIGURE 2.2  Reducing agents affect in vitro DHHC autoacylation and PAT activity. 
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 FIGURE 2.2. Reducing agents affect DHHC autoacylation and PAT activity in vitro. 
 A, DHHC3, DHHS2 (1 pmol), or enzyme buffer were incubated with 1.1 µM 
[3H]palmCoA on ice for the indicated times.  Reactions were stopped with SDS and an 
aliquot was spotted on thin layer chromatography plates that were then developed in 50% 
butanol/20% acetic acid/30% water for 5.5 hr.  The plate was dried, sprayed twice with 
En3Hance solution, and exposed to film at -70°C.  The remaining reaction was resolved 
by SDS-PAGE gels and processed as described in Chapter 4 [PAT ID#529].  B, DHHC3 
was autoacylated with [3H]palmCoA in buffer containing no reducing agent (), 1 mM 
dithiothreitol (DTT, ), or 2 mM β-mercaptoethanol (β-ME, )).  Aliquots representing 
500 fmol DHHC were removed at various times and analyzed by SDS-PAGE and liquid 
scintillation counting [PAT ID#547; n=2].  C, DHHC2 (filled symbols) or DHHS2 (open 
symbols, 500 fmol each) was incubated with 1 µM [3H]palmCoA in buffer containing no 
reducing agent (), 1 mM DTT (), or 1 mM tris(2-carboxyethyl)phosphine (TCEP, ) 
for the indicated time on ice.  DHHS2 was analyzed only at the 12 sec and 60 min time 
points.  Reactions were processed as in B [PAT ID#629; n=2].  D, PAT assay of DHHC2 
or DHHS2 (20 nM) with myrLckNT for 12 min in 0.9 µM [3H]palmCoA with or without 1 
mM DTT [PAT ID#541].  E, Non-enzymatic acylation of myrLckNT (100 pmol) in 1.7 
µM [3H]palmCoA with no reducing agent (), 1 mM DTT (), or 1 mM TCEP () for 
35 min at the indicated pH [PAT ID#633].  F, DHHC2 (5 nM) and/or myrLckNT (1 uM) 
were incubated with 1 µM [3H]palmCoA for 8 min at 25°C either with or without 1mM 
TCEP [PAT ID#631].  G, DHHC3 (10 nM) was incubated with 2 µM myrGαi1 and 1 µM 
[3H]palmCoA for 6 min at 25°C in buffer containing the indicated concentration of TCEP 
[PAT ID#779].  
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DHHC Protein S-Acyltransferases Use A Similar Ping-Pong 
Kinetic Mechanism But Display Different Acyl-CoA Specificities 
 
 
 
 
 
 
 
 
This chapter was reviewed for publication by the Journal of Biological Chemistry.  Dr. 
Maurine Linder and I are coauthors.  The manuscript is accepted pending revision and 
resubmission is anticipated in fall 2011.  
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 Abstract 
 DHHC proteins catalyze the reversible S-acylation of proteins at cysteine 
residues—a modification important for regulating protein localization, stability, and 
activity.  However, little is known about the kinetic mechanism of DHHC proteins.  A 
high performance liquid chromatography (HPLC), fluorescent peptide-based assay for 
protein S-acylation (PAT) activity was developed to characterize mammalian DHHC3.  
Time courses and substrate saturation curves allowed the determination of Vmax and Km 
values for both the peptide N-myristoylated-GCG and palmitoyl-coenzyme A.  DHHC 
proteins acylate themselves upon incubation with palmitoyl-CoA, which is hypothesized 
to reflect a transient acyl-enzyme transfer intermediate.  Single turnover assays with 
DHHC2 and DHHC3 demonstrated that a radiolabeled acyl group on the enzyme 
transferred to the protein substrate, consistent with a two-step ping-pong mechanism.  
Enzyme autoacylation and acyltransfer to substrate displayed the same acyl-CoA 
specificities, further supporting a two-step mechanism.  Interestingly, DHHC2 efficiently 
transferred acyl-chains 14 carbons and longer, whereas DHHC3 activity was greatly 
reduced by acyl-CoAs with chain lengths longer than 16 carbons.  The rate and extent of 
autoacylation of DHHC3, as well as the rate of acyl-chain transfer to protein substrate, 
were reduced with stearoyl-CoA compared to palmitoyl-CoA.  This is the first 
observation of lipid substrate specificity among DHHC proteins and may account for the 
differential S-acylation of proteins observed in cells.   
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 Introduction 
 Protein S-acylation is the posttranslational addition of long-chain fatty acids to 
cysteine residues via a thioester linkage. Unlike other lipid modifications, S-acylation is 
reversible and thus regulated via acylation/deacylation cycles in cells. This regulation is 
important for the activity and localization of key signaling proteins including Ras 
isoforms (38, 176, 177), G-protein α-subunits (178), huntingtin (111, 121), endothelial 
nitric oxide synthase (179), and ion channels (180).  Protein acyltransferases (PATs) 
catalyze the addition of fatty acids to proteins whereas acyl-protein thioestereases (APTs) 
remove them.  Despite the importance of protein S-acylation in these signaling pathways 
and in human diseases (86), little is known about the kinetic mechanism, regulation, and 
substrate specificities of PATs and APTs. 
 Genetic and biochemical studies in yeast have established that a family of integral 
membrane enzymes known as DHHC proteins catalyze protein S-acylation.  While S. 
cerevisiae have seven DHHC PATs, mammalian genomes encode at least twenty-three.  
DHHC proteins are named for a highly conserved Asp-His-His-Cys sequence within a 
larger cysteine-rich domain (DHHC-CRD) that is situated on the cytoplasmic face of the 
membrane between four transmembrane domains (83).  In vitro analyses with 
radiolabeled palmitoyl-CoA (palmCoA) have demonstrated that DHHC proteins are 
sufficient to catalyze the transfer of fatty acids from CoA to cysteine residues within 
target protein substrates. Additionally, DHHC proteins themselves become acylated upon 
incubation with palmCoA, a process called enzyme autoacylation. Mutational analysis 
has revealed that the cysteine residue within the DHHC motif is indispensable for both 
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 palmitoyl-transfer and autoacylation activities (81, 82); however the site of autoacylation 
remains unknown as well as whether autoacylation occurs in cis or trans.  It has been 
hypothesized that DHHC autoacylation reflects a transient acyl-enzyme intermediate with 
DHHC proteins using a two-step ping-pong mechanism to catalyze transfer (81, 82).  
Alternatively, DHHC autoacylation may reflect a modification of the enzyme that is not 
transferred to substrate but serves another function.  
 The fatty acid attached during S-acylation is most often the saturated 16-carbon 
fatty acid palmitate; thus, the process is frequently called S-palmitoylation or simply 
palmitoylation.  However, S-acylation of other chains lengths has been reported. 
Incubation of platelets with [3H]-arachidonate acid (C20:4) resulted in the labeling of 
endogenous G-protein subunits αi, αq, α13, and αz via a thioester linkage (128).  Mass 
spectrometry of fatty acids attached to native rhodopsin revealed that approximately 83% 
are C16 palmitate while the remaining are a mixture of 14:0, 15:0, 16:1, 18:0, 18:1, 18:2, 
20:4, and 22:6 (31).  Metabolic radiolabeling with palmitate versus either C20:4 
arachidonate (129) or C18:0 stearate (127) demonstrated that some proteins are 
preferentially modified with chain lengths other than C16 palmitate.  More recently, 
using click chemistry techniques and alkyl-fatty acids that mimic myristate, palmitate, or 
stearate to enrich for acylated proteins, Hang and coworkers identified proteins from 
Jurkat T cells that selectively labeled with different chain lengths (15).  The mechanism 
responsible for these differences in acyl-chain length attachment remains unclear.  
 In the present study we characterize the kinetic mechanism and lipid substrate 
specificity of DHHC proteins. A high-performance liquid chromatography (HPLC) 
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 fluorescent peptide-based PAT assay is developed to measure rate constants for a 
representative DHHC. Single turnover experiments directly address the question of 
whether DHHC autoacylation is a transient acyl-enzyme intermediate in a two-step ping-
pong mechanism. One corollary of this predicted reaction scheme is that acyl-chain 
lengths capable of being transferred to protein substrates should also be capable of 
autoacylating the DHHC protein. This prediction is tested as well as the mechanism of 
DHHC lipid substrate specificity.  
 
Experimental Procedures 
  Reagents.  The fluorescent peptide myrGCG was synthesized by AnaSpec, Inc 
(San Jose, CA) and consists of N-myristoylated glycine, cysteine protected by a disulfide 
link tert-butyl group, and glycine linked via ethylenediamine to nitro-benzoxadiazole 
(NBD).  Aliquots dried under N2 were stored at -80°C.  [3H]9,10-palmitate (47.7 Ci/mmol) 
was purchased from PerkinElmer Life Science.  [3H]9,10-stearic acid  was purchased from 
Moravek Biochemicals, Brea, CA.  The specific activity reported by the manufacturer for 
[3H]-stearic acid (75 Ci/mmol) exceeded the theoretical maximum specific activity of 
57.6 Ci/mmol.  The theoretical value was used for [3H]-stearic acid calculations.   
[3H]palmCoA for Figures 3.2 and 3.3 was synthesized and purified as described (181).  
For Figure 3.5, [3H]palmCoA and [3H]-stearoyl-CoA were synthesized as described 
except that the detergent n-dodecyl-b-D-maltoside (DDM) replaced Triton X-100.  
Radiolabeled acyl-CoA was separated from free fatty acid by chloroform/methanol 
extraction (28).  Acetonitrile was purchased from Honeywell.  Internal standard 16-12-
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 NBD-PC (1-palmitoyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-4-yl)amino]dodecanoyl}-sn-
glycero-3-phosphocholine) and non-radiolabeled C6- and C10-CoAs were from Avanti 
Polar Lipids.  CoA and the other unlabeled acyl-CoAs were from Sigma. 
 HPLC-based fluorescent peptide PAT assay.  Peptide was deprotected by 
overnight incubation in 77% DMSO, 0.15% DDM, and 7.5 mM TCEP, under argon, 
protected from light at 25°C.  Greater than 90% deprotection was achieved as assessed by 
HPLC before each experiment.  Deprotected peptide was diluted with 50 mM MES pH 
6.4 to 25% DMSO, 0.05% DDM, and 2.5 mM TCEP.  PalmCoA (and later, other acyl-
CoAs) and peptide were mixed in glass test tubes and warmed to 25°C.  Partially purified 
DHHC protein warmed to 25°C was added to start the reaction.  The final reaction was 
50 µL at 50 mM MES pH 6.4, 10% DMSO, 1 mM TCEP, and 0.028% DDM.  Final 
concentrations of DHHC, acyl-CoA, and myrGCG are noted in the figure legends. 
Reactions were stopped with 500 µL dichloromethane and held on ice until all reactions 
were complete.  The reactions were spiked with 250 µL of 0.02 µM 16-12-NBD-PC 
dissolved in methanol as an internal standard and 250 µL aqueous buffer (50 mM MES 
pH 6.4, 250 mM NaCl) to cause phase separation.  This internal standard was chosen 
because it was tagged with NBD similar to the peptide, does not overlap with other 
peaks, and elutes in the same solvent as the palmitoylated peptide, minimizing NBD’s 
high solvatochromic shift (182).  The lower organic phase was collected and extracted 
twice more with 500 µL dichloromethane.  Pooled extracts were clarified with 300 µL 
methanol, dried under N2, and stored at -20°C.  For directly monitoring transfer of 
various acyl-CoA chain lengths, a similar assay was used with 10 µM acyl-CoAs and 5 
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 µM deprotected myrGCG in a final 50 µL reaction.  Addition of DHHC (10 nM) or 
buffer was used to start the reaction, which was incubated at 25°C for 10 min.  Reactions 
were stopped with 500 µL dichloromethane and processed as described above.  
Dried acylated peptides were dissolved in 100 µL isopropanol and then, 100 µL 
0.5 mM TCEP added to reduce disulfide linked peptides. Samples were analyzed using a 
Beckman Coulter Gold HPLC system (508 autosampler, 126NM solvent module, 166NM 
detector) inline with a Jasco FP2020 fluorescence detector with buffer A (20% 
acetonitrile/80% water/0.1% trifluoroacetic acid) and buffer B (100% acetonitrile). For 
each reaction, an aliquot of 50 µL was injected onto a reversed phase Vydac C4 (5 µm, 
300 Å, 4.6 x 250 mm) column equilibrated in 35% buffer B at 1 mL/min.  After 1 min, a 
linear gradient over 5 min increased the mobile phase to 82.5% B, and it was held there 
for 10 min.  The mobile phase was then returned to 35% B over 1.5 min and allowed to 
equilibrate for 3.5 min (Figure 3.1A, dashed line).  UV absorbance was recorded at 254 
nm and fluorescence excited at 465 nm and emission recorded at 531 nm with the gain set 
at 10-100x.  This HPLC method was adapted from work by others (183).  Version 8, 32 
Karat software was used to record data and determine area under the curve for peptide 
and internal standard peaks.  Areas were converted to pmol acylated myrGCG, fit to the 
Michaelis-Menten equation using nonlinear regression, and plotted with Prism 5 
(GraphPad Software, Inc.). 
 Constructs, expression, and protein purification.  Plasmids for murine myrLckNT 
and human DHHC2 were described previously (181).  Mouse DHHC3 was amplified 
from the cDNA (Image Clone 3669723, NM_026917.4) and subcloned into pBlueBac4.5 
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 (Invitrogen; Carlsbad, CA) to encode a protein with a FLAG-His6 sequence 
(GSELRYQAYVDYKDDDDKNSAEFHHHHHH(stop)) appended to the C-terminus of 
DHHC3.  Called pML1117, this plasmid was used to generate catalytically inactive 
DHHS3-FLAG-His6 (pML1354) by site-directed mutagenesis (Stratagene) of Cys157.  
Recombinant baculoviruses were generated as previously described (181).  DHHC-2 and 
-3 WT and DHHS mutants were expressed in Sf9 cells and purified by Ni-NTA metal 
chelate chromatography as previously described except that TriEx™ Sf9 cells and media 
(EMD Chemicals) were used for cell culture.  For peptide studies, direct transfer, and 
acyl-CoA competitions, Ni-NTA elutions were used, whereas for enzyme autoacylation 
studies (Figure 3.5) pooled FLAG affinity-resin elutions were used.  N-myristoylated G-
protein αi1 (myrGαi1) and myrLckNT were co-expressed in E. coli with N-
myristoyltransferase and purified as C-terminal His6-tagged proteins using established 
protocols (181, 184).  
 Direct Transfer from DHHC to protein substrate.  For single turnover 
experiments (Figure 3.2), 350 pmol DHHC protein was incubated with 40 µL FLAG 
affinity resin equilibrated in buffer C (50 mM Tris pH 7.4, 100 mM NaCl, 0.06% DDM, 
5% glycerol, and 1 mM EDTA) at 4°C with end-over-end rotation for 60 min.  Bound 
DHHC was washed three times with 500 µL buffer C and twice with 650 µL buffer D (50 
mM MES pH 6.4, 20 mM NaCl, 0.06% DDM, 5% glycerol, and 1 mM EDTA).  Bound 
DHHC was autoacylated by incubation with buffer D containing [3H]palmCoA (1400 
pmol) for 7 min on ice.  Free [3H]palmCoA was removed by washing with 850 µL buffer 
D eleven times until the radioactive acyl-CoA content of the washes was <5nM.  
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 Radiolabeled DHHC was eluted eight times with 50 mL buffer D containing 0.3 µg/µL 
3X FLAG peptide (Sigma).  Elutions 2-8 were pooled and the time course initiated by the 
addition of 1 µM unlabeled palmCoA and either protein substrate or buffer at 25°C.  
Aliquots were removed at the indicated times and stopped with 5× sample buffer with 2 
mM tris(2-carboxyethyl)phosphine (TCEP) final.  Reactions were divided between two 
SDS-PAGE gels with one set being processed for fluorography and the other for 
scintillation counting using established methods (181).  For single turnover experiments 
with stearate (Figure 3.5C and D), an identical procedure was followed except [3H]-
stearoyl-CoA was used.  
 Acyl-CoA specificity of autoacylation and transfer.  For competition PAT assays, 
[3H]palmCoA and unlabeled acyl-CoA were pre-mixed on ice.  Likewise, DHHC and 
protein substrate were pre-mixed before adding to the lipid substrate mixture and 
incubating 6 min at 25°C.  Final assay concentrations were 20 nM DHHC, 1 µM 
[3H]palmCoA, 10 µM competing acyl-CoA, and either 1 µM myrGαi1 or 0.5 µM 
myrLckNT in a total of 25 µL.  Assays were stopped with 5× sample buffer with 2 mM 
TCEP final and processed for scintillation counting. 
 Hydrolysis of acyl-CoAs (Table 3.2) was determined by incubating DHHC-2, -3 
(45 nM), or buffer with either [3H]palmCoA or [3H]-stearoyl-CoA at 25°C and stopping 
with SDS.  An aliquot of the reaction, equivalent to 5 pmol of the initial acyl-CoA in the 
reaction, was spotted on thin layer chromatography plates (LK6DF silica gel, Whatman) 
and resolved with 50% n-butanol/ 20% acetic acid/ 30% water for 5 hrs.  The plate was 
dried, sprayed twice with EN3HANCE™ autoradiography enhancer spray (PerkinElmer), 
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 and exposed to film at -70°C for 42 hrs.  The regions of the TLC plate containing free 
fatty acids were located by comparison with the film, scraped, and quantitated with 
scintillation counting.  Background free fatty acid was determined from a control reaction 
lacking DHHC and subtracted before fitting the data by linear regression.  To the 
remaining reaction, 5× sample buffer was added and an aliquot representing 1 pmol of 
DHHC protein was resolved on SDS-PAGE gels and processed for scintillation counting 
to monitor enzyme autoacylation.  Analyzing a reaction without DHHC was set as the 
zero time point allowing the data to be fit to a single phase exponential by nonlinear 
regression. 
 
Results  
  Determination of DHHC3 kinetic constants with fluorescent peptide, HPLC-
based PAT assay.  To characterize DHHC proteins mechanistically, we determined 
steady state kinetic parameters with a modified high performance liquid chromatographic 
(HPLC) method initially described for the characterization of PAT activity in cell lysates 
(183).  The advantages of the HPLC-based peptide assay were ease of achieving 
saturating substrate concentrations and elimination of the need for radioactive acyl-CoA 
compounds.  For a palmitoylation site mimic, the three-residue peptide glycine-cysteine-
glycine was synthesized with the N-terminus myristoylated and the C-terminus linked to 
the fluorescent group NBD (myrGCG; Figure 3.1A inset).  A previous study showed that 
myrGCG is taken up by cells and efficiently palmitoylated in a manner that is time-
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 dependent and saturable (185), suggesting it is a good substrate for in vitro palmitoylation 
assays.  
 DHHC2, DHHC3, and DHHC9/GCP16 were individually tested for their ability 
to palmitoylate myrGCG.  DHHC2 and DHHC3 showed similar levels of palmitate 
incorporation, approximately 2.5 times that of DHHC9/GCP16 (unpublished results).  In 
vivo evidence suggests DHHC3 has broad protein substrate specificity (86), and it 
expresses well in insect cells infected with recombinant baculovirus.  Therefore, it was 
chosen for further kinetic analysis.  To determine the linear range of the reaction, a time 
course was performed.  DHHC3, palmCoA, and myrGCG were incubated for various 
times, spiked with an internal standard, and separated on a C4 reversed phase HPLC 
column monitored with a fluorescence detector.  A representative chromatogram is 
shown in Figure 3.1A.  In addition to peaks of unreacted and palmitoylated peptide, a 
peak corresponding to a disulfide-linked myrGCG dimer appears, which results from the 
drying of unprotected myrGCG in the absence of reducing agent.  The area of the 
palmitoylated peptide peak was compared to that of the internal standard and converted 
to pmol of palmitoylated peptide.  At low concentrations of both substrates, the reaction 
was linear for at least the first 6 minutes (Figure 3.1B), however the standard assay was 
limited to 4 minutes before depletion of either substrate occurred.  To determine Km and 
Vmax values, one substrate concentration was held at a constant saturating concentration 
while the other varied.  Saturation with palmCoA and analysis with non-linear regression 
revealed a Vmax of 10.0 pmol/min/pmol of DHHC3 and a Km of 1.5 µM myrGCG (Figure 
3.1C, Table 3.1).  At saturating myrGCG, a Vmax of 10.7 pmol/min/pmol and a Km of 1.2 
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 µM palmCoA were observed (Figure 3.1D).  For both peptide and palmCoA titration 
curves, Vmax values were approximately the same (Table 3.1) as expected under saturating 
conditions.  Both substrate concentrations were varied around their Km values to generate 
data for a double reciprocal, Lineweaver-Burke analysis.  Unfortunately, these data were 
not adequate to distinguish a ternary complex from a ping-pong mechanism (186). 
 Direct measurement of acyl-transfer from acyl-DHHC to protein substrate.  All 
DHHC proteins tested to date autoacylate, a process hypothesized to result from DHHC 
proteins using a ping-pong catalytic mechanism for substrate acylation.  We directly 
tested whether DHHC enzyme autoacylation is a transfer intermediate.  Because DHHC3 
was identified as a PAT for G-protein α-subunits (187), we first confirmed that DHHC3, 
but not the catalytically inactive mutant DHHS3 (DHHC3 C157S), could palmitoylate N-
myristoylated Gαi1 (myrGαi1) above background levels.  Also as expected, DHHC3, but 
not DHHS3, became autoacylated during the assay (Figure 3.2A).  
Using this enzyme/substrate pair, we tracked the transfer of [3H]palmitate from 
[3H]palm-DHHC3 to myrGαi1.  Palmitoyl-DHHC3 was generated by binding partially 
purified DHHC3 to FLAG affinity resin and incubating with [3H]palmCoA to 
autoacylate.  Unreacted [3H]palmCoA was washed out and [3H]palm-DHHC3 was eluted 
with FLAG peptide.  Immunoblotting and fluorography indicated that elutions 2 through 
7 contained [3H]palm-DHHC3 (Figure 3.2B).  The absence of thiol-based reducing agents 
from the buffers was critical for purification of the acylated enzyme.  Elutions were 
pooled and incubated with non-radiolabeled palmCoA and either myrGαi1 or buffer.  
Aliquots removed at various times were stopped, separated by SDS-PAGE, and analyzed 
            55
 by both fluorography and scintillation counting.  Figures 3.2C and 3.2D show that at 
early times most of the [3H]palmitate was attached to the DHHC3 but over time was lost 
from the enzyme and accumulated on myrGαi1.  The rate of transfer of [
3H]palmitate from 
DHHC3 inversely paralleled the rate of gain of [3H]palmitate on myrGαi1 (Figure 3.2D).  
A comparable experiment was performed with DHHC2 and its substrate myrLckNT (181), 
and a similar pattern was observed both by fluorography (not shown) and scintillation 
counting (Figure 3.2E).  A slower loss of [3H]palmitate from both DHHC proteins was 
observed when incubated without a protein substrate; this is likely due to hydrolysis of 
the thioester-attached lipid.  Inclusion of an excess of non-radiolabeled palmCoA (1 µM) 
in the reaction was intended to compete with any residual [3H]palmCoA not removed 
during purification and to drive the reaction to completion.  However, radiolabeled 
palmitate remained associated with DHHC2 and DHHC3 even at extended time courses 
up to 45 minutes.  Spiking the reaction with additional protein substrate after 10 minutes 
did not cause the reaction to proceed further (data not shown). 
 DHHC enzyme autoacylation acyl-CoA chain-length specificity parallels 
substrate acylation specificity.  If enzyme autoacylation is a transfer intermediate, then 
the protein substrate should only acylate with acyl-CoAs that also can acylate the DHHC 
protein.  To test this prediction a competition assay was set up in which a ten-fold excess 
of non-radiolabeled acyl-CoAs of different chain lengths and saturations were used to 
compete with [3H]palmCoA (C16:0) for acylation of enzyme and substrate.  For both 
DHHC2 and DHHC3, the level of enzyme autoacylation paralleled that of substrate 
acylation for each competing acyl-CoA tested (Figure 3.3A and B).  Together with Figure 
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 3.2 and work by others (175), these data strongly suggest that DHHC autoacylation 
represents a transient transfer intermediate and DHHC proteins use a two-step ping-pong 
mechanism for catalysis. 
 DHHC2 and DHHC3 display different acyl-CoA specificities.  In Figure 3.3, a 
difference in lipid substrate profiles for DHHC2 and DHHC3 was observed.  For 
DHHC2, acyl-CoAs of 14 carbons and longer inhibited [3H]palmCoA labeling of both 
substrate and enzyme.  However, with DHHC3 only myristoyl-, palmitoyl-, and 
palmioleoyl-CoA were effective and longer acyl-CoAs competed less well.  The 
competition assays in Figure 3.3 suggested that DHHC2 transfers fatty acids longer than 
16 carbons.  However, the reduction in the [3H]palmitate labeling could be caused by 
these longer acyl-CoAs acting through a distinct mechanism, for example, by acting as 
inhibitors.  The difference in acyl-CoA specificities between the DHHCs could also result 
from the different protein substrates used.  To address both of these issues, DHHC-2 and 
-3 were tested in the HPLC-based PAT assay to directly monitor their ability to transfer 
various fatty acids to the same substrate, myrGCG.  DHHC2 transferred fatty acids from 
all acyl-CoAs chain lengths tested (Figure 3.4) consistent with it having a broad 
specificity for long chain acyl-CoAs as seen in the competition assay (Figure 3.3B).  In 
contrast, DHHC3 displayed a narrower lipid substrate profile, transferring only myristate 
(C14) and palmitate (C16) at significant levels.  Thus, the difference in acyl-CoA 
specificity between DHHC2 and DHHC3 was independent of the protein or peptide 
substrate used.   
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 Discussion 
 In this study we examined the mechanism DHHC proteins use to catalyze acyl-
transfer and their acyl-CoA specificity.  An HPLC, peptide-based PAT assay enabled us 
to determine kinetic constants for each substrate.  Single turnover assays confirmed the 
hypothesis that DHHC autoacylation represents the transient acyl-enzyme transfer 
intermediate of a two-step ping-pong mechanism.  Acyl-CoA competition assays 
provided further evidence for this mechanism and revealed an unexpected difference in 
acyl-CoA preferences between DHHC2 and DHHC3.  This difference was shown to 
result from DHHC3’s reduced ability to autoacylate with and transfer acyl-chains longer 
than 16-carbon palmitate. 
 Kinetic mechanism of DHHC-mediated protein acylation.  Others and we had 
previously hypothesized that DHHC proteins use a two-step mechanism based on their 
ability to autoacylate.  Ungermann and coworkers used a “two-step reaction mechanism” 
to describe the activity of the yeast DHHC protein Pfa3p (188).  However, their two steps 
referred to the binding of protein substrate by the DHHC and a second event 
encompassing the entire catalytic reaction.  More recently, Mitchell et al. proposed a two-
step reaction mechanism in the classical kinetic sense to differentiate steps within the 
catalytic reaction (175).  Using TLC to monitor free palmitate production, they showed 
that Erf2p has palmCoA hydrolase activity that occurs with a rapid autoacylation step and 
a slower second step involving the transfer of palmitate to water.  Addition of Ras2p, a 
palmitoylation substrate, increased Erf2p consumption of palmCoA but slowed 
production of free palmitate, suggesting the palmitate was now being transferred to 
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 Ras2p in the second reaction step.  Using single turnover assays, we isolated acylated-
DHHC protein and confirmed that it can transfer its attached lipid group to a protein 
substrate.  This confirmed DHHC autoacylation represents a transient transfer 
intermediate and thus supports the hypothesis that DHHC proteins use a two-step transfer 
mechanism.  
 To further characterize the mechanism of DHHC-mediated acylation, kinetic 
constants were determined for each substrate using an HPLC, peptide-based PAT assay.  
These constants were determined by fitting substrate titration data to the Michaelis-
Menten equation.  Michaelis-Menten assumes that enzyme and substrate(s) are freely 
diffusible in solution.  However, DHHC proteins are integral membrane enzymes and 
were bound to detergent micelles in our assays.  It is unclear whether DHHC proteins 
acquire their substrates from bulk solution or by horizontal diffusion within a lipid 
environment.  Surface dilution kinetic models account for limited two-dimensional 
horizontal diffusion and offer an alternative model for fitting the data (189).   
  In single turnover assays, it is interesting to note that in no case did all the lipid 
transfer off the DHHC, even at later time points.  Additionally at these later times, a 
similar amount of enzyme remained labeled regardless if the acyl-group was transferred 
to protein substrate or was hydrolyzed.  It is unknown whether this reflects enzyme that is 
inactive with lipid still attached or whether there are secondary acylation sites that are not 
transferred and are less susceptible to hydrolysis.  The stoichiometry of DHHC3 
autoacylation was 0.5 palmitate per DHHC (Figure 3.5A), similar to a value of 0.65 
reported for the yeast DHHC protein Erf2p (175).  These data suggest that the 
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 stoichiometry of autoacylation in vitro is one acyl chain per DHHC.  The autoacylation 
site is predicted to be the conserved cysteine of the DHHC motif.  Mutation of this 
canonical DHHC cysteine blocks autoacylation and transfer, but there is no direct 
evidence that this is the acylated cysteine.  Proteomic analysis of DHHC proteins isolated 
from cells has revealed that a three-cysteine motif (CCX7-13C(S/T) in the cytoplasmic C-
terminal domain of DHHC5, 6, and 8 is palmitoylated (20).  This motif is not conserved 
among DHHC proteins, and it seems unlikely that palmitoylation of this domain 
represents the acyltransfer intermediate.  However, it has been proposed that that 
intramolecular transfer of the acyl group from the catalytic cysteine to the distal 
palmitoylated cysteines could occur (20).  Mapping of the sites of in vitro autoacylation 
is necessary to resolve this issue.  
 It is likely that the two-step transfer mechanism described here and elsewhere is 
common to all DHHC proteins.  For DHHC2 and DHHC3, and for the yeast Ras PAT 
Erf2/Erf4 (175), the first step of autoacylation was rapid, suggesting that within cells, 
DHHC proteins in the presence of acyl-CoAs may persist in the acylated state poised for 
transfer.  Regulation of protein acylation may depend on controlling the association 
between DHHC proteins and their substrates.  Indeed, following activity blockade in 
neurons, DHHC2 was shown to translocate to postsynaptic densities, colocalize with one 
of its substrates, post-synaptic scaffolding protein PSD-95, and increase PSD-95 
acylation (93).  Alternatively, the acylation machinery may be constitutively active and 
deacylation is a regulated step.  To date, no mechanism of post-translational modification 
has been described for the regulation of DHHC proteins or deacylating enzymes.  While 
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 we are beginning to develop a mechanistic understanding of DHHC proteins, more work 
is needed to understand their structure and regulation.  
 Fatty Acyl-CoA Substrate Specificity.  Investigating the kinetic mechanism of 
DHHC proteins lead us to determine their acyl-CoA chain-length specificity.  
Surprisingly, a difference in acyl-CoA specificity was observed between DHHC3 and 
DHHC2.  In the competition assay shown in Figure 3.3, the reduction of [3H]-palmitate 
incorporation into substrate by non-radiolabeled acyl-CoAs was presumed to be because 
unlabeled acyl-groups were transferred onto the substrate.  Indeed, this was likely the 
case for DHHC2 and all acyl-CoAs tested in Figure 3.4 as they could be transferred.  
However, with DHHC3 and C18- or C20:4-CoA and to a lesser degree with C18:1, very 
little acyl-group was transferred to the peptide (Figure 3.4), yet all three caused about 
70% reduction of [3H]-palmitate incorporation in the competition assay.  Thus, it is likely 
acyl-CoAs longer than 16 carbons were interacting with DHHC3 in such a way as to slow 
acylation with palmitate.  This was confirmed for DHHC3, in which the extent of 
autoacylation and the rate of transfer of stearate was slower than with palmCoA.  The 
differential sensitivity of DHHC PAT activity to different acyl-CoAs suggests a possible 
mode of regulation in cells where changes in the availability of different species of acyl-
CoA would impact which DHHC proteins were active and accordingly, which  proteins 
are modified. 
 Hydrocarbon rulers for filtering different lipid lengths have been characterized for 
other enzymes. Protein N-myristoyltransferase (NMT) shows exquisite specificity for 14 
carbon acyl-CoAs.  Crystal structures of NMT bound to substrate analogs reveal that 
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 specificity is achieved by measuring the fatty acid between an oxyanion hole binding the 
carbonyl and the floor of the hydrophobic pocket.  Furthermore, a hydrophobic groove 
induces bends in myristate that further restrict acyl-chain saturation and branching (69).   
Fen1p and Sur4p subunits of the very-long chain fatty acid (VLCFA) synthase complex 
also display acyl-chain length specificity and, similar to DHHC proteins, are polytopic 
integral membrane enzymes (190).  The sizing mechanism results from the distance 
between a cytoplasmic active site and a lysine residue extending from a transmembrane 
helix within the lipid bilayer.  By shifting the lysine up and down turns of the helix, acyl-
chain specificity was altered.  While DHHC3 does not contain lysine residues within its 
predicted TMDs, it does contain charged residues that may behave similarly in restricting 
acyl-chain length.  The structural basis for DHHC lipid substrate specificity provides a 
new area for investigation.  
 Inhibitors of DHHC proteins will be important tools for studying DHHC biology 
within cells, as well as having potential as therapeutic agents.  An increasing number of 
DHHC proteins have been linked to different human diseases (86).  We and others have 
attempted to find and characterize DHHC inhibitors with limited success (181).  To date, 
2-bromopalmitate (2-BP) remains the best DHHC inhibitor available, even though it 
lacks specificity among DHHC proteins as well as other cellular enzymes.  Given the 
two-step mechanism of DHHC catalysis, it might be predicted that inhibitors of the 
autoacylation step would block acylation by all DHHC proteins.  However, data 
presented here indicate that the autoacylation step displays acyl-CoA specificity.  Thus it 
is likely that inhibitory compounds can be found that are selective for different DHHC 
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 proteins, possibly through acyl-CoA analogs with different fatty acid chains.  The success 
with developing potent and highly selective kinase inhibitors that occupy the ATP 
binding site encourages efforts to identify small molecules that target DHHC 
autoacylation.  
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 Table 3.1.  Kinetic parameters for DHHC3 analyzed with fluorescent peptide, 
HPLC-based PAT assay 
 
 Km 
(µm) 
Vmax 
(pmol/min/pmol) 
MyrGCG titration at  
10 µM palmitoyl-CoA (n = 4) 1.5±0.3 10.0±1.2 
Palmitoyl-CoA titration at  
10 µM myrGCG (n = 3) 1.2±0.2 10.7±1.7 
 
 
 
Table 3.2.  Hydrolysis rates of different acyl-CoAs with DHHC3 and DHHC2   
 
 C16:0 palmitoyl-CoA 
(pmol/min/pmol) 
C18:0 Stearoyl-CoA 
(pmol/min/pmol) 
DHHC3 (n = 2) 0.027 0.008 
DHHC2 (n = 2) 0.030 0.038 
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Figure 3.1.  Fluorescent peptide, HPLC-
based kinetic characterization of DHHC3. 
A, Structure of the tripeptide substrate 
N-myristoylated Gly-Cys-Gly tagged via 
ethylenediamine with fluorescent NBD 
(myrGCG, inset).  The elution profile of 
myrGCG following reversed-phase chroma-
tography.  After in vitro reaction with acyl-
CoA and DHHC3, myrGCG was spiked with 
internal standard (16-12-NBD-PC), extracted, 
dried, and chromatographed using the gradi-
ents (dashed line) shown with Buffer A (20 % 
ACN/80% water/0.1% TFA) and Buffer B 
(100% ACN). Identity of peaks is indicated.  
B, Time course for the enzymatic palmitoyla-
tion of myrGCG (0.5 μM) with palmCoA (0.5 
μM).  Nonlinear regression fit the overall 
reaction to a single phase exponential, whereas 
values for 0 to 6 min were fit to a straight line 
(R2 = 0.99).  C, Michaelis-Menton fit to 
myrGCG titration with DHHC3 (5 nM) and 
saturating palmCoA (10 µM) reacting for 4 
min.  D, Michaelis-Menton fit to palmCoA 
titration with DHHC (5 nM) and saturating 
myrGCG (10 µM) reacting for 4 min.  A repre-
sentative of three independent experiments is 
shown for each.
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Figure 3.2.  Autoacylated DHHC proteins transfer their acyl chain to protein substrate.  A, DHHC3 
palmitoylates N-myristoylated Gαi1 (myrGαi1).  DHHC3-FLAG-His6 (20 nM), the catalytically inactive 
mutant DHHC3 C157S (DHHS3, 20 nM), or buffer were incubated with myrGαi1 (1 μM) and 
[3H]palmCoA (1 μM) for 6 min at 25°C.  The reaction was stopped and [3H]palmitate incorporation was 
detected by fluorography (lower panel) or quantitated by scintillation spectrometry as described in Experi-
mental Procedures.  B, Partially purified DHHC3 (350 pmol, LOAD) was immobilized on FLAG affinity 
resin and the flow through (FT) collected. The column was washed (Wash) and prepped (Prep) for incuba-
tion with on-column acylation buffer (OCAB) containing [3H]palmCoA for 7 min on ice.  Unbound 
[3H]palmCoA was washed out (WOP) with eleven column volumes.  Radiolabeled DHHC3 was eluted and 
analyzed for DHHC3 by immunoblotting and [3H]palmitate incorporation.  C, [3H]palm-DHHC3 was 
incubated either alone or with myrGαi1 in the presence of unlabeled palmCoA to monitor a single transfer 
event.  After incubation at 25°C for the indicated times, reactions were stopped and analyzed as in A by film 
(C) or scintillation counting (D).  D, Incubation of [3H]palm-DHHC3 () with myrGαi1 () or alone () 
as in C were processed for scintillation counting. Data were fit to single phase exponential using nonlinear 
regression.  E, Similar to D, [3H]palm-DHHC2 () was incubated with myrLckNT () or alone ().  
Exposures were at -70°C.  Data are representative of one of three independent experiments.
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Figure 3.3.  Acyl-CoA chain-length specificity of DHHC enzyme autoacylation parallels substrate 
specificity.  A, Non-radiolabeled acyl-CoAs of the indicated chain length and saturation (10 µM), 
coenzyme A (CoA), or buffer were added to reactions containing [3H]palmCoA (1 µM),  DHHC3 (20 nM) 
and myrGαi1 (1 µM).  Reactions were incubated at 25°C for 6 min and processed for quantitation by 
scintillation spectroscopy.  [3H]-palmitate incorporation in the presence of each competitor was normalized 
to the average of two reactions lacking competitor.  For DHHC3 without competitor, the average 100% 
values were 112, 114, and 65 fmol whereas for myrGαi1 they were 646, 630, and 585 fmol.  Mean and 
standard error of the mean are shown for three independent experiments.   B, Similar to A, except with 
DHHC2 (20 nM) and myrLckNT (0.5 µM).  For DHHC2 without competitor, the average 100% values were 
56, 46, and 30 fmol, whereas for myrLckNT they were 1035, 914, and 886 fmol. 
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Figure 3.4.  DHHC2 displays broader lipid substrate specificity than DHHC3.  DHHC2, DHHC3 (10 
nM), or enzyme buffer were incubated with myrGCG (5 µM) and acyl-CoAs (10 µM) of the indicated 
chain length for 10 min at 25°C.  Reactions were stopped, extracted, and processed on an HPLC C4 
column.  For each reaction, the fluorescence chromatogram of myrGCG elution is shown between 9.5 and 
15 min.
DHHC3
DHHC2
Buffer
C14-CoA C16-CoA C18-CoA C18:1-CoA C20:4-CoA
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Figure 3.5.  Hydrolysis, enzyme autoacylation, and direct transfer of DHHC2 and DHHC3 with C18 
stearate and C16 palmitate.  A and B, Enzyme autoacylation for DHHC3 (A) or DHHC2 (B) was deter-
mined by adding sample buffer to aliquots of the reactions described in Table 3.1 representing 1 pmol of 
DHHC and resolving it by SDS-PAGE.  The DHHC band was excised and processed for scintillation count-
ing.  Analyzing a reaction lacking any DHHC was set as the zero time point allowing the data to be fit to a 
one phase exponential by nonlinear regression.  Symbols are:  DHHC3 with C16-CoA,  DHHC3 with 
C18-CoA,  DHHC2 with C16-CoA, and  DHHC2 with C18-CoA.  C and D, Single turnover assays 
with [3H]stearoyl-DHHC.  C, Incubation of [3H]stearoyl-DHHC3 () with myrGαi1 () or [3H]stearoyl-
DHHC3 alone () for the indicated times and processed for scintillation counting.  D, Similar to C, 
incubating [3H]stearoyl-DHHC2 () with myrLckNT () or [3H]stearoyl-DHHC2 alone () for the 
indicated times.  Data were fit to a single exponential. 
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 Chapter 4 
 
 
 
 
 
2-Bromopalmitate and 2-(2-Hydroxy-5-nitro-benzylidene)-
benzo[b]thiophen-3-one Inhibit DHHC-Mediated  
Palmitoylation In Vitro 
 
 
 
 
 
This chapter was published in Jennings, B. C., Nadolski, M. J., Ling, Y., Baker, M. B., 
Harrison, M. L., Deschenes, R. J., and Linder, M. E.  2009.  Journal of Lipid Research.  
50:233-242.  Marissa Nadolski and Yiping Ling provided purified yeast proteins.  
Meredith Baker and Marietta Harrison provided plasmids to express wildtype and mutant 
LckNT.  I generated and purified the other constructs and conducted all of the 
experiments. 
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 Abstract 
 Pharmacologic approaches to studying palmitoylation are limited by the lack of 
specific inhibitors.  Recently, screens have revealed five chemical classes of small 
molecules that inhibit cellular processes associated with palmitoylation (Ducker et al. 
(2006) Mol Cancer Ther 5:1647-1659).  Compounds that selectively inhibited 
palmitoylation of N-myristoylated vs. farnesylated peptides were identified in assays of 
palmitoyltransferase activity using cell membranes.  Palmitoylation is catalyzed by a 
family of enzymes that share a conserved DHHC cysteine-rich domain.  In this study, we 
evaluated the ability of these inhibitors to reduce DHHC-mediated palmitoylation using 
purified enzymes and protein substrates.  Human DHHC2 and yeast Pfa3 were assayed 
with their respective N-myristoylated substrates, Lck and Vac8.  Human DHHC9/GCP16 
and yeast Erf2/Erf4 were tested using farnesylated Ras proteins.  Surprisingly, all four 
enzymes showed a similar profile of inhibition.  Only one of the novel compounds, 2-(2-
hydroxy-5-nitro-benzylidene)-benzo[b]thiophen-3-one (Compound V), and 2-
bromopalmitate (2BP) inhibited the palmitoyltransferase activity of all DHHC proteins 
tested.  Hence, the reported potency and selectivity of these compounds were not 
recapitulated with purified enzymes and their cognate lipidated substrates.  Further 
characterization revealed both compounds blocked DHHC enzyme autoacylation and 
displayed slow, time-dependent inhibition but differed with respect to reversibility.  
Inhibition of palmitoyltransferase activity by Compound V was reversible, whereas 2BP 
inhibition was irreversible.    
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 Introduction 
 Protein palmitoylation is the post-translational attachment of palmitate or other 
long-chain fatty acids to cysteine residues in proteins via a thioester linkage (reviewed in 
(6, 191).  The functional consequences of protein palmitoylation are diverse and include 
effects on protein localization, trafficking, and stability.  In contrast to other lipid 
modifications, palmitoylation is reversible.  Consequently several cellular processes use 
palmitoylation-depalmitoylation cycles to affect the localization and function of key 
proteins.  
 Protein acyltransferases (PATs) catalyze the addition of palmitate (83).  Genetic 
and biochemical studies in yeast uncovered a family of integral membrane enzymes that 
mediate palmitate addition to proteins that are modified on the cytoplasmic face of cell 
membranes.  The hallmark of this family of proteins is the DHHC (Asp-His-His-Cys) 
cysteine-rich domain.  A family of seven DHHC proteins is present in S. cerevisiae and 
homology searches have identified at least 23 genes that encode DHHC proteins in 
mammals.  PAT activity is dependent upon the DHHC domain and mutation of the 
cysteine of the DHHC motif abolishes catalytic activity of the enzyme. 
 Palmitoylated proteins are prominent in cell signaling pathways and are 
particularly abundant in the nervous system (192).  Signal transducers, receptors, ion 
channels, and scaffolds are among the targets of palmitoyltransferases.  Finding the 
enzymes responsible for palmitoylation has accelerated our understanding of the role of 
palmitoylation in both native and disease states.  An example is HIP14 (DHHC17), a 
DHHC protein initially identified as huntingtin-interacting protein 14 (193).  HIP14 has 
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 been linked to palmitoylation of huntingtin, SNAP-25, cysteine string protein, and other 
neuronal substrates (121).  Palmitoylation of htt by HIP14 influences htt localization and 
protects it from aggregation (111).  In flies, HIP14 is essential for presynaptic function 
and plays a role in neurotransmitter release, likely through palmitoylation of SNAP-25 
and cysteine string protein (194, 195).  
 Oncogenic Ras proteins are associated with numerous human tumors.  
Palmitoylation of H- and N-Ras plays a key role in trafficking between the plasma 
membrane and Golgi apparatus (83), as well as facilitating the oncogenic potential of 
activating Ras mutations (196).  Several DHHC proteins have been linked to cancer.  
Human HIP14 is oncogenic, promoting colony formation in soft agar and tumor 
formation in nude mice (122).  HIP14 mRNA is upregulated in numerous tumors (152).  
DHHC9, a PAT for H- and N-Ras in vitro, is upregulated in microsatellite stable tumors 
(140), whereas DHHC2 is a putative tumor suppressor (92).  
 The importance of palmitoylation in physiology and pathophysiology suggest that 
palmitoylation inhibitors could be beneficial for the treatment of diseases, as well as tools 
for probing the role of palmitoylation in cellular processes.  Inhibitors of palmitoylation 
have been limited to 2-bromopalmitate (2BP), cerulenin, and tunicamycin.  The most 
commonly used, 2BP inhibits palmitoylation in cells (197) and PAT activity of DHHC 
proteins in vitro (123).  However, 2BP also inhibits fatty acid CoA ligase (198) and other 
enzymes involved in lipid metabolism (199).  Similarly, cerulenin and tunicamycin 
inhibit palmitoylation within cells but also inhibit other cellular process including fatty 
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 acid synthesis (200) and N-glycosylation (165, 167), respectively.  Consequently, there is 
a need to identify specific inhibitors of palmitoylation. 
 Smith and coworkers have developed high throughput screens for palmitoylation 
inhibitors (152).  The screens yielded compounds that fell into five chemical classes and 
a representative compound from each class was further characterized.  Cell membranes 
from MCF-7 cells were used as a source of PAT activity to evaluate the representative 
compounds’ ability to inhibit palmitoylation in vitro.  Fluorescently labeled peptides 
mimicking either N-myristoylated, palmitoylated proteins, such as Gα subunits and Src-
related tyrosine kinases, or mimicking C-terminally farnesylated, palmitoylated proteins, 
like N- and H-Ras, were used as substrates.  Four of the representative compounds 
showed a preference for inhibiting palmitoylation of the Ras-like peptide (average of 
76% inhibition) but not the myristoylated peptide (15% inhibited).  Conversely, the fifth 
compound displayed the reverse, inhibiting palmitoylation of the myristoylated peptide 
(74%) but not the Ras-like peptide (17%).  Thus, it appears these compounds not only 
inhibit palmitoylation but also display substrate specificity.  Additionally, IC50 values 
were reported in low to sub-micromolar range (11.8 to 0.5 µM) (152). 
 We sought to further investigate the properties of these compounds.  Because cell 
membranes were used as a source of PAT activity, it is unclear whether the inhibitors 
reduced palmitoylation by directly blocking DHHC proteins.  Here we tested if these 
compounds inhibit DHHC-mediated palmitoylation of protein substrates.  Additionally, 
by using DHHC proteins that display different substrate preferences, the ability of these 
inhibitor compounds to specifically inhibit palmitoylation of farnesylated substrates vs. 
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 N-myristoylated substrates was examined.  Compounds that inhibited DHHC-mediated 
palmitoylation were further characterized.  
 
Experimental Procedures: 
  Inhibitor Compounds and Reagents.  Inhibitor compounds (Figure 4.1) were 
purchased from ChemBridge Corporation (San Diego, CA).  [3H]palmitoyl-CoA was 
synthesized using [3H]palmitate (45 Ci/mmol, PerkinElmer Life Sciences), Coenzyme A 
(Sigma), and acyl CoA synthase (Sigma) as described (26) with the following 
modification.  Following synthesis, [3H]palmitoyl-CoA was separated from palmitate by 
chloroform/methanol extraction (28) and subsequently purified on a C8 reversed phase 
cartridge (26).  
 Plasmids.  Standard molecular biology techniques were used to manipulate DNA.  
All plasmid constructs were verified by DNA sequence analysis.  DHHC2 was expressed 
using recombinant baculovirus.  DHHC2 was prone to proteolysis and several constructs 
were made with affinity tags at both ends to generate a virus that would yield intact 
DHHC2 protein.  Oligonucleotide sequences used to generate plasmids are available 
upon request.  Human DHHC2 was amplified from Image Clone 4398300 (GenBank ID 
BF983682) and subcloned as a KpnI fragment into pBlueBacHis2B (Invitrogen; 
Carlsbad, CA).  This yielded pML850, encoding His6Express-DHHC2. pML850 was 
digested with HindIII and SalI to permit ligation with a double stranded oligonucleotide 
linker  that encodes a HindIII site, the FLAG epitope, an EcoRI site, a His6 epitope, a stop 
codon, and a SalI site.  This yielded pML892, encoding His6Express-DHHC2-FLAG-
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 His6.  pML892 was cut with BglII and AgeI, purified, and ligated with double stranded 
oligonucleotides encoding the calmodulin binding peptide (CBP) followed by an XbaI 
site to generate His6Express-CBP-DHHC2-FLAG-His6 (pML943).  Catalytically inactive 
DHHS2 (pML1023) was generated by site directed mutagenesis (Stratagene) of pML943.   
 Plasmids expressing the N-terminal 226 amino acids of Lck (LckNT) and 
LckNT(C3,5S) were constructed as follows.  The murine Lck cDNA encoding residues 1-
226 was amplified as a NdeI-XhoI fragment and subcloned into the bacterial expression 
vector pET23a(+) yielding pML1008.  This construct was used as template to generate 
the C3,5S mutant (pML1175) using a mutagenic primer to amplify the 5’ end of the 
coding sequence.  
 Yeast N-myristoyltransferase (yNMT) was expressed using pBB131 (201).  The 
plasmid pML1067 was constructed to express human NMT1 by excising the yeast NMT1 
gene from pBB131 with BglII and EcoR1 and replacing it with human NMT1 flanked by 
pBB131 vector sequences.  Human NMT1 was amplified from pBB218 and overlap 
extension PCR was used to generate flanking pBB131 vector sequences (202).  
 Recombinant baculovirus and insect cell culture.  Sf9 insect cells were purchased 
from ATCC and grown in suspension culture medium (IPL-41 (Gibco) supplemented 
with 10% heat inactivated bovine growth serum, yeastolate, Pluronic F68, 50 mg/mL 
gentamycin, and 250 ng/mL fungizone) at 27°C with rotation at 110 rpm.  Recombinant 
baculoviruses were generated using Invitrogen’s Bac-n-Blue™ transfection kit with 
pML943 and pML1023 and plaque-purified. 
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  Purification of DHHC proteins.  For DHHC2, Sf9 insect cells were inoculated 
with baculovirus expressing human DHHC2 N-terminally tagged with His6-Express-CBP 
and C-terminally tagged with FLAG-His6.  Infected cells were collected by centrifugation 
and washed with cold PBS 61 hr post infection.  Cell pellets were stored at -80°C until 
purification.  All purification steps were performed at 4°C and all buffers contained the 
protease inhibitors 1 mM PMSF, 1-5 µg/mL pepstatin A, 1.4 µg/mL aprotinin, 1.6 µg/mL 
leupeptin, and 1.6 µg/mL lima bean trypsin inhibitor.  A cell pellet of ~5 mL (from 335 
mL Sf9 culture) was quickly thawed at 37°C and suspended in 35 mL cavitation buffer 
(50 mM Tris pH 7.4, 150 mM NaCl, 10 mM β-ME, 1 mM EDTA).  Cells were lysed by 
nitrogen cavitation (30 min at 700 psi).  The lysate was centrifuged at 700g for 10 min to 
remove nuclei and unbroken cells.  The postnuclear supernatant was centrifuged at 
100,000g for 30 min to generate P100 and S100 fractions.  P100 membranes were 
suspended in 9 mL extract buffer (50 mM Tris pH 7.4, 200 mM NaCl, 10 mM β-ME, and 
10% glycerol) by sequential passage through 14, 18, and 25 gauge needles.  Total protein 
concentration was determined using Bio-Rad’s Bradford protein assay (Hercules, CA).  
Membranes were diluted with extract buffer and 10% n-dodecyl-β-D-maltoside detergent 
(DDM; Dojindo Laboratories, Japan) to give a final protein concentration of 2 mg/mL in 
1% DDM.  The extract was again passed through a 25G needle and incubated 80 min 
with end-over-end rotation.  The extract was cleared at 100,000g for 30 min, diluted 1:1 
with extract buffer (no DDM), and gravity-flowed twice through a column of 3.4 mL 
Ni2+-nitrilotriacetic acid-agarose resin (Ni-NTA; Qiagen) equilibrated in wash buffer (50 
mM Tris pH 7.4, 100 mM NaCl, 3 mM β-ME, 10% glycerol, 0.1% DDM, and 20 mM 
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 imidazole).  The resin was washed with 60 mL wash buffer and eluted with wash buffer 
containing 200 mM imidazole (2 3 mL) and wash buffer containing 500 mM imidazole 
(3 3 mL).  Ni elutions 1-4 were pooled, diluted 1:1 with buffer A (50 mM Tris pH 7.4, 
100 mM NaCl, 10% glycerol, 0.1% DDM, 1 mM EDTA, and 0.2 mM β-ME), and passed 
thrice through a column of 300 µL ANTI-FLAG® M2-agarose affinity gel (Sigma) 
equilibrated in buffer A.  The resin was washed with 14 mL buffer A and eluted with 5  
250 µL buffer A containing 0.23 mg/mL FLAG peptide (Sigma) with a 10 min 
incubation for each elution.  The concentration of enzyme was determined by 
extrapolation from a linear curve with known concentrations of bovine serum albumin 
using Sypro Ruby protein gel stain (Molecular Probes) and quantitation with a StormTM 
860 (Amersham Biosciences).  
 DHHS2 purification paralleled that of DHHC2 through nickel affinity 
chromatography.  The identity of purified DHHC2 or DHHS2 was confirmed by 
immunoblots using antibodies at the following dilutions: anti-FLAG 1:3000 (Stratagene), 
anti-Express 1:1500 (Invitrogen), and goat anti-mouse IgG secondary conjugated to HRP 
at 1:2000 (MP Biomedicals, OH).  
 For human DHHC9/GCP16, Sf9 cells were co-infected with baculoviruses 
expressing DHHC9-myc-His6 and FLAG-GCP16 (114) and cultured for 73 h before 
harvesting.  DHHC9/GCP16 was purified similarly to DHHC2.  
  The purification of Erf2/Erf4p was performed as previously described (203).  
 For partially purified yeast Pfa3, YPH499 was transformed with a Pfa3-His6-Flag 
pESC expression construct.  Yeast were cultured and cell membranes prepared as 
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 described (91).  Pfa3-His6-Flag was extracted from cell membranes in 1% Triton X-100 
at 5 mg/mL total protein in extraction buffer (50 mM Tris pH 8.0, 100 mM NaCl, 10% 
glycerol, 5 mM β-ME, and 0.1 mM PMSF) rotating for 1 hr at 4˚C.  Insoluble material 
was pelleted at 200,000g for 20 min.  The detergent extract (7.5 mg total protein) was 
diluted 1:1 in extraction buffer and allowed to bind to 2 mL Ni-NTA resin for 1 hr at 4°C.  
The resin was reconstituted in a column and washed with 20 mL wash buffer (50 mM 
Tris pH 8.0, 100 mM NaCl, 10% glycerol, 5 mM β-ME, 0.1% Triton X-100, 0.1 mg/mL 
bovine liver lipids (Avanti Polar Lipids), and 0.1 mM PMSF).  Bound proteins were 
eluted with elution buffer (50 mM Tris pH 8.0, 100 mM NaCl, 10% glycerol, 200 mM 
imidazole, 1 mM β-ME, 0.1 % Triton X-100, and 0.1 mg/ml bovine liver lipids) and four 
2 mL fractions were collected.  Fractions one and two were pooled, aliquoted, and stored 
at -80°C. 
 Purification of PAT substrates.  Mouse N-myristoylated LckNT (myrLckNT) was 
purified from ER2566 E.coli (New England Biolabs) harboring pBB131 (201) and 
pML1008.  Cells were grown in Luria-Bertani broth containing 50 µg/mL kanamycin and 
50 µg/mL ampicillin at 37°C with shaking at 250 rpm for 4 hr.  IPTG was added to 0.6 
mM final concentration and the temperature was reduced to 30°C for 5 hr.  Cells were 
harvested by centrifugation at 3080g for 20 min at 4°C.  Cell pellets were washed with 
cold PBS, collected by centrifugation at 3800g for 17 min at 4°C, flash frozen in liquid 
N2, and stored at -80°C until needed.  Purification steps were performed on ice or in a 
4°C cold room.  Cell pellets representing 400 mL culture were quickly thawed at 30°C, 
suspended in 11 mL lysis buffer (50 mM Tris pH 7.4, 8 mM β-ME, 150 mM NaCl, 1 
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 µg/mL pepstatin A, 1.6 µg/mL leupeptin, 1.6 µg/mL lima bean trypsin inhibitor, and 1.4 
µg/mL aprotinin), and passed thrice through a French Press cell.  The soluble fraction 
was collected by centrifugation at 76,500g for 30 min.  To enrich for myristoylated-
LckNT, this soluble fraction was extracted twice with 1.3 mL 10% Triton X-114 detergent 
(Sigma) essentially as described (204) except incubations were for 5 min at 37°C.  The 
detergent phases were pooled, diluted to 0.2% Triton X-114 (135 mL total), and gravity 
loaded onto a 3 mL Ni-NTA column equilibrated in wash buffer (50 mM Tris pH 8.0, 
300 mM NaCl, 10 mM imidazole, and 8 mM β-ME).  The column was washed with 150 
mL wash buffer and eluted 5  3 mL with elution buffer (50 mM Tris pH 7.4, 100 mM 
NaCl, 300 mM imidazole, 8 mM β-ME, and 10% glycerol).  Elution 2 was used for 
subsequent PAT assays.  The concentration of myrLckNT was determined by 
extrapolation from a linear curve with known concentrations of bovine serum albumin 
using Coomassie Blue gel stain and quantitation with ImageJ software (NIH).  C3,5S 
myrLckNT was expressed in BL21(DE3) E.coli transformed with pML1067 and 
pML1175 and purified as described for WT.  The identity of purified protein was 
confirmed by immunoblotting with mouse monoclonal anti-Lck (3A5, sc-433) purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA). 
 Yeast N-myristoylated Vac8 was purified by ion-exchange and hydroxylapatite 
chromatography as described (203).  Prenylated Ras proteins were expressed in yeast 
from the galactose-inducible vector pEG(KG) and purified as described (81, 203).  The 
GST-Ras2(HV) construct consists of the C-terminal 35 amino acid residues of yeast Ras2 
fused to GFP.  Full-length mammalian H-Ras was fused to GST.  
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  In vitro PAT assays.  Inhibitors were dissolved and serially diluted to 100X stocks 
in 100% DMSO.  Stocks were diluted to 5X with TED (20 mM Tris pH 7.4, 1 mM 
EDTA, and 1 mM DTT).  Equal volumes (5 µL) of DHHC enzyme and 5X inhibitor 
solutions were pre-incubated for various times and temperatures as indicated in figure 
legends.  Protein substrates diluted in TED (5 µL) were pre-mixed with reaction hot mix 
(RHM; 10 µL; 250 mM MES pH 6.4, 1 mM DTT, 1.2-3.4 µM [3H]palmCoA) and 
incubated at the same temperature as enzyme/inhibitor mix.  This substrate mixture (15 
µL) was added to the enzyme/inhibitor mix to start the reaction and incubated as indicted 
for each figure.  The reactions (25 µL) were stopped by addition of 5X gel loading buffer 
with final 2 mM DTT (6.25 µL).  Except for assays of reversibility, all inhibitor 
concentrations shown are for the final 25 µL reaction.  Stopped reactions were heated for 
60 sec at 95°C before resolution by SDS-PAGE.  Gels were stained with Coomassie 
Blue, destained, and scanned.  Protein substrate bands were excised from the gel, placed 
into scintillation vials, solubilized in 500 µL Soluene 350 (PerkinElmer) at 50°C for at 
least 3 hr, and quantitated by liquid scintillation spectroscopy.  
 Enzyme autoacylation assays without inhibitors (Figure 4.2, right panel) were 
performed similar to inhibitor profile assays described above.  Briefly, 500 fmol of 
enzyme was incubated in 0.82 µM [3H]palmCoA for 10 min at 25°C in RHM.  Reactions 
were stopped with gel loading buffer and resolved by SDS-PAGE.  Gels were stained, 
destained, soaked in 1 M sodium salicylate/15% methanol for 20 min, dried onto filter 
paper, and exposed to film at -80°C for 8 days.  Enzyme autoacylation assays with 
inhibitors (Figure 4.5) were performed similar to inhibitor profile assay except without 
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 protein substrate.  Briefly, 250 fmol of DHHC2 was pre-incubated with inhibitor for 8 
min at 25°C.  Pre-warmed RHM was added to give a final concentration of 1.1 µM 
[3H]palmCoA in 25 µL and the reaction proceeded for 2 min before stopping with 5X gel 
loading buffer.  Reactions were processed similar to those in Figure 4.2.  
 The assay for reversibility was similar to those above, except the initial reaction 
volume was 200 µL and 25 µL aliquots were removed at the indicated times.  DHHC2 
was pre-incubated for 30 min at 25°C with inhibitor at the first concentration indicated.  
Equilibrated substrates in RHM with either DMSO or inhibitor were used to dilute the 
enzyme/inhibitor 40-fold to the second concentration indicated and to start the reaction, 
which was maintained at 25°C.  At the indicated times, aliquots (25 µL) were removed 
from the reaction, stopped with gel loading buffer, and processed as above.  In 
experiments to measure time-dependent inhibition, DHHC2 (100 fmol) was pre-
incubated 30 min at 25°C with inhibitor or a DMSO control.  Reactions were started by 
addition of either both substrates in RHM to enzyme/inhibitor mix (pre-incubation) or 
both substrates and inhibitor to enzyme/DMSO mix (no pre-incubation).  Reactions (25 
µL, 2% DMSO final) were incubated 7 min at 25°C before stopping and processing as 
above.  Data were graphed and analyzed using Microsoft Excel and GraphPad Prism 5.0.  
 
Results  
 Purification of active DHHC2.  The predicted targets of the palmitoylation 
inhibitors identified by Ducker et al. are the DHHC proteins.  Furthermore, the pattern of 
specificity shown by the inhibitors in assays using cell membranes as a source of 
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 palmitoyltransferase activity suggests that some of the inhibitors would more potently 
inhibit DHHC proteins that modify farnesylated substrates, whereas others would be 
more effective inhibitors of PATs for N-myristoylated substrates.  To test these 
predictions, we purified mammalian and yeast DHHC PATs that display the appropriate 
substrate specificity.  Yeast Erf2/Erf4 is a PAT for yeast Ras (81), but displays little 
activity toward Vac8, an N-myristoylated protein (203).  Conversely, yeast Pfa3 
palmitoylates Vac8 (91) but not Ras2 (203).  Mammalian DHHC9/GCP16 palmitoylates 
H-Ras in vitro, but has little or no activity for N-myristoylated Gia1 (114).  
 We sought to identify a mammalian DHHC protein that has robust activity for an 
N-myristoylated substrate.  Preliminary experiments revealed that the nonreceptor 
tyrosine kinase Lck, a protein palmitoylated at cysteine residues near the myristoylated 
N-terminus, was a good substrate for DHHC2 (data not shown).  To further characterize 
this interaction, we expressed human DHHC2 with epitope tags at both the N- and C-
termini to aid in the purification of full-length enzyme.  Detergent extracts from 
membranes were passed sequentially over nickel and FLAG affinity resins to generate 
purified enzyme (Figure 4.2, left).  Immunoblotting revealed full-length protein was 
isolated (Figure 4.2, center).  
 In all DHHC proteins characterized to date, PAT activity has been coupled with 
incorporation of palmitate into the DHHC protein itself, a process termed enzyme 
autoacylation (83).  Although it is uncertain whether this process represents an acyl-
enzyme transfer intermediate, autoacylation serves as a read out for functional enzyme.  
Purified DHHC2 incorporated [3H]palmitate derived from [3H]palmitoyl CoA.  This 
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 reaction was specific as neither heat-treated DHHC2 nor DHHS2, a mutant predicted by 
homology to be catalytically inactive (83), showed radiolabeling (Figure 4.2, right).  
Thus, we have purified DHHC2 and shown it to be functionally active as monitored by 
autoacylation.  
 DHHC2 palmitoylates myrLckNT at cysteines 3 and 5.  To test Lck as a substrate 
for DHHC2, we used a model substrate consisting of the N-terminal myristoylation, 
palmitoylation motif (SH4 domain) and the SH3 and SH2 domains (LckNT).  This 
fragment is more easily purified than the full-length protein that includes the kinase 
domain.  To confirm that in vitro palmitoylation of LckNT was occurring at cysteine 
residues palmitoylated in vivo, we also expressed and purified C3,5S myrLckNT.  Lck is 
palmitoylated in vivo at Cys3 and Cys5, which may differentially regulate Lck 
localization (205).  Lck has two additional cysteines near the amino terminus (Cys20 and 
Cys23) that are required for binding coreceptors CD4 and CD8 (206).  Because 
myristoylation facilitates subsequent palmitoylation both in vivo and in vitro (26, 207), 
we purified wild type and mutant LckNT from E. coli coexpressing human N-
myristoyltransferase (NMT) to produce N-myristoylated substrates.  Metabolic labeling 
with [3H]myristic acid indicated that both proteins were myristoylated in this system and 
that mutation of the palmitoylation sites did not affect myristoylation (see Supplemental 
Figure 4.S1).  
 Wildtype and C3,5S myrLckNT were purified and assayed for their ability to be 
acylated by DHHC2 in an in vitro PAT assay.  Incubation of either form of myrLckNT 
with [3H]palmCoA and enzyme buffer did not result in incorporation of radiolabel in 
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 myrLckNT as monitored by scintillation counting or fluorography (Figure 4.3, first 3 
lanes).  When 200 fmol of DHHC2 was included in the reaction, greater than 1500 fmol 
of [3H]palmitate was incorporated into wild type myrLckNT, indicating that transfer is 
catalytic.  Less than 100 fmol of [3H]palmitate was incorporated into C3,5S myrLckNT by 
DHHC2.  When autoacylation-defective DHHS2 was assayed, no radiolabel was 
incorporated into myrLckNT (Figure 4.3, last 3 lanes).  The low levels of radiolabel in 
C3,5S myrLckNT may indicate that DHHC2 weakly palmitoylates myrLckNT at other 
cysteine residues nonspecifically. 
 Evaluation of potential PAT inhibitors using enzyme-substrate pairs.  Using the 
three established enzyme-substrate pairs described above along with DHHC2 and 
myrLckNT, we sought to determine if the PAT inhibitors identified by Ducker et al. 
blocked DHHC-mediated palmitoylation and displayed the predicted substrate 
specificity.  We obtained and tested four of the five compounds along with 2-
bromopalmitate (2BP; Figure 4.1).  Compound IV (CIV; 2-(2-fluoro-benzyl)-1-phenyl-
1,2,3,4-tetrahydro-pyrrolo[1,2,-a]pyrazine) was not available from commercial sources 
and was not tested here.  For inhibitor PAT assays, the inhibitor was pre-incubated with 
DHHC protein, followed by the addition of both protein substrate and [3H]palmCoA that 
had been pre-mixed and equilibrated at the assay temperature.  To remain in the linear 
range for each reaction, concentrations, temperature, and lengths of incubations varied for 
each pair and are listed in the legend to Figure 4.4.  
 Overall, less potent and specific inhibition was observed than expected (Figure 
4.4).  For all pairs tested, 2BP was the best inhibitor displaying an average IC50 of ~10 
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 µM.  This result confirmed that 2BP inhibits DHHC-mediated palmitoylation in vitro as 
shown previously for DHHC15 (123).  Compound V (CV) was initially described as a 
selective inhibitor of N-myristoylated, palmitoylated protein but not farnesylated, 
palmitoylated proteins, with an IC50 of 0.5 µM for an N-myristoylated peptide (152).  As 
shown here, CV inhibited all DHHCs tested but was less potent than 2BP, displaying a 
higher IC50 for three of the four enzyme-substrate pair.  The remaining compounds (CI, 
CII, and CIII) were previously demonstrated to inhibit PAT activity toward a farnesylated 
peptide mimicking Ras, with IC50 values of 4 to 12 µM.  When tested against the DHHC 
Ras PATs, DHHC9/GCP16 and Erf2/Erf4, little or no inhibition was observed for any of 
the enzymes, even at the highest concentration tested (100 µM, Figure 4.4).  Thus with 
the DHHC enzyme-substrate pairs tested, the predicted selectivity of these compounds 
was not observed.  
 2-Bromopalmitate and Compound V inhibit enzyme autoacylation.  2BP and CV 
reduced DHHC-mediated palmitoylation.  Accordingly, we characterized these 
compounds further.  Because 2BP and CV affected all four enzyme-substrates pairs 
equally, DHHC2 and myrLckNT were chosen as a representative pair for further 
experiments.  To date all DHHC proteins that display PAT activity also autoacylate.  
Thus, we determined the effect of 2BP and CV on enzyme autoacylation.  As seen in 
Figure 4.5, both compounds inhibited enzyme autoacylation, with 2BP being more potent 
at blocking enzyme radiolabeling than CV.  
 Evaluation of reversibility and time-dependent inhibition.  We next wanted to 
assess whether the inhibition of PAT activity by 2BP and CV was reversible or 
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 irreversible.  DHHC2 was pre-incubated with either 2BP or CV at the first, pre-dilution 
concentration indicated in Figure 4.6A.  This preformed enzyme-inhibitor complex was 
diluted 40-fold with buffer containing both protein and lipid substrates to give the second 
inhibitor concentration indicated.  The lack of recovery of PAT activity following 
dilution of 2BP compared to the inhibited controls maintained at persistent concentrations 
of inhibitor indicates that 2BP is an irreversible inhibitor (Figure 4.6A, left side; square 
symbols relative to filled symbols).  In contrast, when CV was similarly diluted, 
approximately 70 percent of PAT activity was recovered compared to the inhibited 
control maintained at the diluted concentration of CV (Figure 4.6A, right side).  This 
indicates that the inhibitory effect of CV is reversible.  
 Finally, because inhibitor profiles for each enzyme-substrate pairs were done 
following pre-incubation with inhibitor, we wanted to assess whether 2BP and CV 
displayed time-dependent inhibition (also called slow-binding inhibition; Figure 4.6B).  
During one set of conditions (without inhibitor pre-incubation) substrates and 2BP or CV 
were premixed and the assay started by addition of DHHC2 pre-incubated with a DMSO 
control.  Alternatively, under a second set of conditions (with inhibitor pre-incubation), 
DHHC2 and 2BP or CV were pre-incubated 30 minutes before addition of both substrates 
to initiate the reaction.  For both compounds, an increase in inhibitor potency following 
pre-incubation was observed with the curves shifting to the left (Figure 4.6B).  This 
suggests that both CV and 2BP are time-dependent inhibitors of DHHC2 PAT activity.  
Higher concentrations of CV were not tested because of limitations in the solubility of the 
compound. 
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Discussion 
 As advances are made in the palmitoylation field it is becoming increasingly clear 
that DHHC proteins play an important role in both native and disease states.  DHHC 
proteins have been identified that are responsible for palmitoylating proteins involved in 
cell growth (114, 122), maintaining vascular homeostasis (179), neurotransmitter receptor 
trafficking (123), and cell-cell adhesion (208).  DHHC proteins have also been linked to 
several diseases including cancer (122, 140, 152), Huntington’s disease (111), and mental 
retardation (139).  Identification of potent and specific palmitoylation inhibitors that 
target DHHC proteins could lead to novel therapies, as well as provide tools to 
investigate palmitoylation’s roles in cellular processes.  
 With that in mind, we sought to determine whether DHHC proteins were targets 
of the palmitoylation inhibitor compounds described by Ducker et al. (152).  We found 
that one of the four compounds, CV, behaved similarly to 2BP, in that it inhibited all four 
of the DHHC proteins tested.  Both 2BP and CV inhibited autoacylation of the enzyme, 
which is tightly correlated with the ability to transfer palmitate to substrate.  It is 
unknown whether autoacylation represents an acyltransfer intermediate.  However, the 
loss of autoacylation with inhibitors that also block transfer to substrate is consistent with 
such a mechanism.  Furthermore, the ability of CV to inhibit autoacylation, a property 
common to all DHHC proteins, suggests that it will not be selective for different DHHC 
proteins.  
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  Inhibition of DHHC2 PAT activity by 2BP was irreversible.  This was not 
unexpected as 2BP has been shown to irreversibly inhibit fatty acid metabolism (209, 
210), as have other halogenated fatty acid analogs (211).  Additionally, others have 
previously hypothesized that 2BP forms an irreversible bond with PATs (212).  In 
contrast the inhibition by CV was mostly reversible.  This is perhaps not unexpected in 
that CV does not contain any highly reactive centers (Figure 4.1).  Both 2BP and CV 
displayed time-dependent inhibition, albeit to different degrees.  Time-dependent 
inhibition is considered an advantage in a pharmacological setting because the enzyme is 
inhibited for longer periods of time (213).  This, plus the fact that 2BP inhibits other 
enzyme families (198, 199), suggest that CV may be a good candidate for future 
structure-activity relationship studies with substituent side-chain replacement focused on 
enhancing potency and specificity. 
 We were unable to detect significant inhibition of DHHC proteins by three of the 
compounds tested, nor did CV display selective inhibition of DHHC PAT activity for N-
myristoylated substrates.  Several possible explanations could account for the differences 
between the original report describing these compounds and those documented here.  
Ducker et al. (152) used MCF-7 cell membranes as a source of PAT activity.  DHHC 
proteins have not been studied in these cells, but given the large family size, it is likely 
that multiple DHHC proteins are expressed.  Reverse transcriptase-PCR has detected 
mRNA for both DHHC2 and DHHC9 in MCF-7 cells (unpublished observations).  
However, it is possible that DHHC proteins other than DHHC2 and DHHC9/GCP16 are 
possibly more sensitive to these compounds.  Phylogenetic analysis of DHHC sequences 
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 from humans and yeast place DHHC9 and Erf2 within a larger subfamily (DHHC5, 8, 9, 
14, 18, 19, and Erf2).  Similarly, DHHC2 and Pfa3 cluster with a different group of 
DHHC proteins (DHHC2, 3, 7, 15, 20, and Pfa3) (123).  DHHC proteins less closely 
related to these two groups were not tested.  
 An important difference between the two studies is the substrates that were tested.  
Ducker et al. assayed short fluorescent, lipidated peptides (myristoyl-Gly-Cys and Cys-
Leu-Cys-farnesyl,O-methyl).  We assayed full-length (myristoyl-Vac8 and farnesyl-H-
Ras) or larger protein fragments (HVRas2, the farnesylated hypervariable domain of Ras, 
and myristoyl-LckNT).  It remains to be determined whether Lck and H-Ras are in vivo 
substrates, as well as in vitro substrates of DHHC2 and DHHC9/GCP16.  However, the 
yeast enzymes and their substrates have been validated both genetically and 
biochemically (81, 91, 214), and display strong preferences for their respective substrates 
relative to the other lipidated substrates (203).  Accordingly, these yeast enzymes and 
their substrates represented an excellent system to test the inhibitors for substrate 
specificity. 
 Inhibition of PAT activity in MCF-7 membranes by the compounds may be 
dependent on a membrane environment.  DHHC proteins are integral membrane proteins 
and the surrounding lipid environment can affect both rate and specificity of such 
enzymes (160).  The hydrophobic compounds tested here may act indirectly, disrupting 
the membrane surrounding DHHC proteins rather than directly interacting with them.  
Alternatively, DHHC proteins within a lipid bilayer may adapt a conformation that makes 
them more susceptible to these compounds.  Because the DHHC proteins tested here 
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 were purified and assayed in detergent micelles, effects of the compounds on DHHC 
proteins that require a lipid membrane would have been missed.  Initial attempts at 
reconstituting DHHC proteins into liposome were unsuccessful and more work is needed 
in this area.  
 Finally, it is possible that proteins other than DHHC proteins are targets of these 
compounds.  A study of the palmitoylproteome in yeast suggests that DHHC PATs 
account for most cellular palmitoylation events (16).  In mammals, secreted proteins such 
as the morphogens Hedgehog and Wnt, as well as the peptide hormone ghrelin, are 
posttranslationally modified with fatty acids through the action of membrane-bound O-
acyltransferases (MBOAT) (6, 215).  Modification of these secreted proteins occurs in 
the lumen of the secretory pathway.  To date only one MBOAT protein has been 
characterized biochemically (8).  It is unknown if these activities could account for 
palmitoylation of the peptides in the MCF-7 cell membranes.  
 The finding that CV is an inhibitor of DHHC PATs and the antitumor activity 
reported for all of the compounds makes them interesting reagents for further study.  
Future investigations into DHHC enzymology and mechanism will likely aid the search 
for specific and potent PAT inhibitors.  
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Figure 4.1. Structure and names of inhibitor compounds used in this study.  
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Figure 4.2.  Purification of human DHHC2 and catalytically inactive DHHS2.  DHHC2 was expressed 
in Sf9 cells and purified sequentially by nickel chelate and FLAG affinity chromatography.  Catalytically 
inactive DHHS2 was purified by nickel affinity chromatography; the fifth elution is shown.  Purified 
DHHC2 and DHHS2 were detected by Sypro staining (left) and immunoblotting with anti-Express 
antibody (center).  DHHC2, but not DHHS2, autoacylates (right).  DHHC2, DHHS2, or heat inactivated 
DHHC2 (500 fmol each) were incubated in 0.8 μM [3H]palmCoA at pH 6.4 for 10 min.  The reactions were 
stopped with SDS sample buffer and processed for fluorography.  The film was exposed for 8 days. 
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Figure 4.3.  DHHC2 palmitoylates myrLckNT at cysteines 3 and 5.  Purified DHHC2, DHHS2 (200 
fmol), or enzyme buffer was mixed with purified myrLckNT (25 pmol) on ice.  Reaction buffer was added 
to give a final concentration of 0.8 μM [3H]palmCoA in 50 μL and incubated at 25°C for 7 min.  The 
reaction was stopped with SDS sample buffer and divided between two SDS-PAGE gels, which were 
stained and destained.  A, The region containing myrLckNT was excised from one gel, solubilized with 
Soluene, and the amount of [3H]palmitate present determined by scintillation counting.  B, The second gel 
was processed for fluorography and exposed to film at -80°C for 90 hr.  MyrLckNT was detected by immu-
noblotting reactions run without radioactive palmCoA. 
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Figure 4.4.  Inhibitor profiles for DHHC proteins.  Inhibitor profiles for each enzyme-substrate pair were 
carried out as described in the text.  A, Partially purified yeast Pfa3 (5 μL) was pre-incubated with inhibitor 
for 8 min at 30°C.  MyrVac8 and [3H]palmCoA were mixed, warmed to 30°C, and added to the reaction at 
final concentrations of 0.5 μM and 0.8 μM, respectively.  The reaction proceeded for 10 min at 30°C before 
stopping with SDS sample buffer.  B, Purified human DHHC2 (100 fmol) was pre-incubated 8 min at 25°C 
with inhibitors.  MyrLckNT and [3H]palmCoA were added to give final concentrations of 0.5 μM and 0.8 
μM, respectively, and the reaction proceeded for 7 min at 25°C before stopping.  C, Purified yeast Erf2/Erf4 
(100 fmol) was pre-incubated 8 min at 25°C with inhibitors.  [3H]palmCoA and the farnesylated hypervari-
able region of Ras2 fused to GST were added to give final concentrations of 0.9 μM and 1.0 μM, respec-
tively, and the reaction proceeded for 10 min at 25°C before stopping.  D, Purified human DHHC9/GCP16 
(150 fmol) was pre-incubated 5 min on ice with inhibitors.  [3H]palmCoA and the farnesylated H-Ras fused 
to GST were added to give final concentrations of 0.9 μM and 1.2 μM, respectively, and the reaction 
proceeded for 7 min at 25°C before stopping.  Values represent the means ± the standard error of the mean 
determined from three independent experiments.
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Figure 4.5.  Inhibitor effect on enzyme autoacylation.  DHHC2 (250 fmol) was pre-incubated with 
inhibitor and assayed as described in Experimental Procedures.  The film was exposed for 8 days.
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Figure 4.6.  Reversibility and time-dependent inhibition.  Experiments were performed as described in 
Experimental Procedures.  A, Reversibility of 2BP and CV was tested by incubating DHHC2 (100 fmol) 
with the first concentration indicated for 30 min at 25°C.  This mix was diluted 40-fold with both substrates 
to the post-dilution concentration indicated, incubated at 25°C, and aliquots removed at the indicated time 
points.  B, Time-dependent inhibition was evaluated by pre-incubating enzyme with inhibitors at the 
indicated concentrations or DMSO for 30 min at 25°C.  Both substrates without or with inhibitor were 
added to start the reaction, which was incubated at 25°C for 7 min before stopping.  Values represent the 
means ± the standard error of the mean determined from three independent experiments. 
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Supplemental Figure 4.S1.  Recombinant WT and C3,5S LckNT are myristoylated.  E. coli 
BL21(DE3) were transformed with pML1008 (WT LckNT-His6), pML1175 (C3,5S LckNT-His6), or empty 
pET21 vector with or without pML1067 (human NMT1).  Cultures were grown at 37°C to OD600 = 0.7-0.8 
and induced with 0.3 mM IPTG for 100 min at 30°C.  A portion of the culture (1 mL) was incubated with 
1.7 nmol [3H]myristic acid (50 μCi, PerkinElmer Life Sciences) for 4 hr at 30°C.  Cells were collected by 
centrifugation and washed in cold PBS.  Whole cell lysates were made by addition of 200 μL 1.5X sample 
buffer with 30 mM DTT and heating to 95°C for 4 min with vortexing.  Samples were frozen overnight at 
-20°C.  The next day thawed samples were spun at 10,000g for 2 min and 3 μL of each were separated by 
SDS-PAGE and processed for fluorography or immunoblotting with α-Lck (1:5000).  The dried gel was 
exposed to film at -80°C for 16 hr.  The dark bands present in lanes 2 and 3 indicate that both WT and C3,5S 
LckNT are being myristoylated in E. coli. 
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 Chapter 5 
 
 
Implications and Future Directions 
 
 
Findings of the thesis   
 In this thesis, I have described the development and utilization of protein S-
acyltransferase (PAT) assays to examine the mechanism of DHHC proteins.  When this 
work began, the DHHC protein family had recently been identified as the group of 
enzymes responsible for catalyzing protein S-acylation.  Of the DHHC proteins that had 
previously been isolated, all incorporated palmitate when incubated with radiolabeled 
palmCoA.  Although this was hypothesized to reflect an acyl-enzyme intermediate (81, 
82), it was possible that DHHC acylation represented a non-transferable modification 
consistent with other integral membrane proteins being stably acylated on cysteine 
residues adjacent to transmembrane domains.  Thus, the hypothesis that DHHC 
autoacylation reflected a transfer intermediated needed to be tested.  Assays initially used 
for the characterization of PAT activity in tissues and cell lines were optimized for 
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 DHHC proteins.  The detrimental effects of thiol-based reducing agents on DHHC 
activity were reported and assay conditions altered.   
 Using these new assay conditions, the predicted catalytic mechanism of DHHC 
proteins was determined.  Single turnover assays provided evidence to support the 
hypothesis that autoacylated DHHC proteins represent a transient acyl-enzyme transfer 
intermediate.  These results supporting a two-step ping-pong mechanism of transfer that 
agree well with results by others published recently (175).  During this investigation it 
was discovered that DHHC proteins display different acyl-CoA specificities and the 
mechanism of this specificity was investigated.  For DHHC3 the reduced ability to 
transfer longer chain fatty acids was not due to increased hydrolysis of the acyl-
intermediate but rather reduced formation of acyl-enzyme and a significantly reduced rate 
of transfer to protein substrate.  These differences in DHHC acyl-CoA specificity provide 
a mechanism to explain the differences in acyl-chain lengths observed on native S-
acylated proteins isolated from cells and tissues.  
 Assays of PAT activity were also used to evaluate the specificity and potency of 
potential protein S-acylation inhibitors with DHHC proteins.  At the initiation of these 
studies, previously described inhibitors of protein acylation were limited to 2-
bromopalmitate (2BP), cerulenin, and tunicamycin.  While capable of reducing S-
acylation within cells, these compounds were also known to inhibit other enzymes and 
thus, lacked specificity.  Nevertheless, tunicamycin and cerulenin were assayed for their 
ability to block DHHC-mediated acylation and found to have no effect on PAT activity 
(Table 2.2).  This lack of specific S-acylation inhibitors motivated others to develop 
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 screens for finding new inhibitors.  Ducker et al published five representative compounds 
they found using cell-based screening methods and follow-up studies with assays of PAT 
activity in crude cell membranes (152).  I directly tested whether these compounds and 
2BP were capable of inhibiting DHHC-mediated protein acylation.  My studies revealed 
that two compounds, 2BP and Compound V, were capable of inhibiting DHHC-mediated 
protein acylation, and their mechanism of inhibition was characterized.  Given the 
importance of DHHC proteins in human diseases, my results stress the importance of 
testing lead compounds directly on intended targets and outline a methodology to do so.  
 
Future Directions  
 The following model is proposed for the catalytic mechanism of DHHC proteins 
based on my investigation and the published work of others.  A DHHC protein initially 
binds a long-chain acyl-CoA and, in a reaction that is dependent on the cysteine residue 
of the DHHC motif, forms a thioester bond with the acyl group.  This enzyme 
autoacylation step of the reaction is rapid and may display burst kinetics.  A free thiol 
group on a protein substrate, which can bind before (188) or after autoacylation (Figure 
3.2 and 3.5), then enters the active site.  In the acyltransfer step, the acyl chain attached to 
the DHHC is transferred to the free thiol and a new thioester bond is formed in a reaction 
that is dependent on the first histidine of the DHHC motif (81, 175).  Release of the 
newly S-acylated protein generates free enzyme that then becomes available for another 
round of catalysis.  Given the hydrophobic character of the protein substrate, I speculate 
that the acylated protein product dissociates from the enzyme and diffuses within the 
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 plane of the membrane.  The mechanistic insight into DHHC catalysis provided by this 
thesis work represents a significant advance from knowledge available when these 
investigations began.  However, the details of the DHHC catalytic mechanism remain to 
be determined.   
 Acyl-CoA source.  How DHHC proteins acquire their acyl-CoAs in cells is 
unknown.  Cytosolic free long-chain acyl-CoA (LCA) concentrations are calculated to be 
in the 2-10 nM range even though total cellular concentrations may be as high as 160 µM 
(36).  The difference reflects that fact that most LCAs are compartmentalized in the 
mitochondria or other organelles, membrane-bound, cleaved by hydrolases, or bound by 
acyl-CoA binding protein (ACBP) or fatty acid bind protein (FABP).  Given that other 
enzymes utilize LCAs and the rapid kinetics observed for cellular acylation-deacylation 
cycles (38, 216), it is predicted that if DHHC proteins used free LCAs, the low cytosolic 
pool would rapidly become depleted.  One possibility is that DHHC protein acquire their 
LCAs through lateral diffusion in the membrane.  This could require the LCA to slide 
into a binding pocket, capable of determining chain-length preference, and may suggest 
membrane fluidity surrounding the DHHC could regulate substrate accessibility.  An 
alternative is that DHHC proteins could use ACBP-bound LCAs.  Supporting this 
substrate source, the integral membrane enzyme acyl-CoA:lysophospholipid 
acyltransferase (LAT) prefers ACBP-bound LCAs over free acyl-CoAs (217).  
Furthermore, previous work in our lab has shown that an unidentified PAT activity is 
capable of utilizing ACBP-bound acyl-CoAs (39).  If DHHC proteins acquire LCAs from 
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 ACBP in cells, then inclusion of ACBP in PAT assays may better represent physiological 
conditions.  
 Kinetic rate constants.  Little quantitative information is available on the rates of 
individual steps within the reaction pathway.  Based on the work here, it is known that 
the enzyme autoacylation step occurs rapidly reaching maximum incorporation of 
radiolabeled acyl group in less than ten seconds, relative to a slower transfer step.  
Measurements less than this time scale are not possible with the discontinuous radiolabel-
based PAT assay.  Combining the CoA production coupled-assay (175) and stop-flow 
spectroscopy could allow more accurate determination of autoacylation rates.  Rates for 
different enzymes as well as with different acyl-CoAs could be used to quantify acyl-
CoA and protein substrate preferences.  Rates could also be used to quantitatively 
determine the contribution of other membrane anchoring signals such as N-myristoylation 
or prenylation to the reaction.  Although the acyltransfer step is slower than 
autoacylation, it is unknown whether acyl group transfer  or release of acyl-substrate is 
the rate-limiting step.  Measuring rate constants could address this.  Measuring reaction 
rates for DHHC proteins with mutations within the conserved DHHC cysteine rich 
domain (CRD) could help determine the role of individual residues within the reaction 
mechanism and provide insight into structure-function relationships.  
 Mapping the acyl-DHHC attachment site.  The cysteine of the DHHC motif is 
required for enzyme autoacylation and is likely the site of acyl attachment, although this 
has not been shown.  DHHC proteins have seven conserved cysteine residues within the 
DHHC cysteine rich domain (DHHC-CRD) and an additional 1 to 15 non-conserved 
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 cysteine residues; the average DHHC has a total of 16 cysteine residues.  It is likely that 
S-acylation occurs outside the DHHC motif.  Indeed for DHHC-5, -6, and -8, a tricysteine 
motif in the C-terminal tail has been shown to be acylated (20).  Mapping the modified 
residue(s) of the acyl-enzyme intermediate would provide a target residue for inhibitor 
design and would aid in determining the stoichiometry of autoacylation.  Knowing the 
stiochiometry would allow enzyme concentrations to be based on functional enzyme 
concentrations rather than total enzyme, which is skewed by misfolded, aggregated, and 
inactivated protein.  Our early attempts to identify the acylated peptide by mass 
spectrometry of trypsin-digested acyl-DHHC have been unsuccessful.  Two 
improvements are suggested: enrichment of the acyl-peptide and removal or replacement 
of the fatty acid prior to mass spectrometry.  Acyl resin-assisted capture (acyl-RAC) (18) 
or acyl-biotin exchange (ABE) (218) are newer, nonradiolabel-based methods of 
analyzing protein S-acylation and accomplish both improvements.  
 Oligomerization of DHHC proteins.   It is unknown whether DHHC proteins 
function as multimers.  Co-immunoprecipitation of epitope-tagged DHHC3 and DHHC7 
expressed in cells suggests that these DHHC proteins can form homo- and 
heteromultimers (219).  Further suggesting DHHC proteins may interact directly, ectopic 
expression of DHHS-15 or AAHC-15 in cells resulted in a dominant negative phenotype 
with reduced activity observed for cotransfected wildtype DHHC15 and DHHC2 (123).  
For DHHC9 and the yeast ortholog, Erf2, heterodimers are formed with cognate binding 
partners GCP16 and Erf4, respectively.  Although the function of these binding partners 
is unknown, multimerization of other DHHC proteins may serve a similar function.  If 
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 DHHC proteins form oligomers, then cooperativity between subunits is possible and this 
would affect interpretation of kinetic data.   
 Oligomerization of DHHC proteins also allows a type of behavior called half-of-
sites reactivity.  This is a behavior in oligomeric enzymes in which the number of active 
subunits is less, typically one-half, than the total number of subunits.  This can be caused, 
for example, by substrate binding to one subunit of a dimer and inducing a 
conformational change in the other subunit that blocks substrate binding, and thus is a 
type of negative cooperativity (220).  The integral membrane protein phospholipase A 
(OMPLA) is an example of an enzyme displaying this behavior (221).  In kinetic studies 
this mode of reactivity presents itself as the maximal stoichiometric yields of either an 
enzyme intermediate or the product of a single turnover assay as being only half the 
number of enzyme active sites.  The maximal stoichiometries of DHHC autoacylation 
observed were 0.5 palmitate per DHHC3 (Figure 3.5A) and 0.65 palmitate per Erf2/Erf4 
(175), consistent with a half-of-sites mechanism.  However, other explanations, such as 
inactive enzyme, could also explain DHHC stoichiometries less than one.  In single 
turnover assays we observed approximately half the acyl-enzyme transferring its acyl 
group to protein substrate.  Again, this could be explained by either a half-of-sites model 
or by enzyme inactivated after autoacylating.  Knowing if DHHC proteins form 
oligomers would be the first step in testing this mechanism.  
 Structural basis for acyl-CoA specificity.  The structural basis for the observed 
differences in acyl-CoA specificity for DHHC proteins remains unclear.  When tested by 
an in vitro competition PAT assay, DHHC15-mediated incorporation of radiolabeled 
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 palmitate was reduced 90% by non-labeled palmCoA but only 57% by non-labeled C18 
stearoyl-CoA (123).  This may suggest that DHHC15, similar to DHHC3, is less able to 
transfer acyl chains longer than 16-carbon palmitate.  A structural basis for these 
observed specificities may reside in the DHHC transmembrane domains (TMDs).  It has 
been shown for the multienzyme complex fatty acid synthase (FAS) that a lysine residue 
regulates final acyl-CoA chain length by protruding from TMDs in Fen1 or alternative 
subunit Sur4 at different distances from the catalytic core.  Examining their predicted 
membrane topology, three TMDs of DHHC3 contain charged residues at the midpoint of 
the bilayer that are not present in DHHC2, which has broader acyl-CoA specificity.  
Swapping TMDs between these DHHCs and site-directed mutagenesis could reveal 
whether this region controls acyl-CoA specificity.  If this is found not to be the case, 
mutations at these sites may still be informative as these charged residues buried within 
DHHC3’s TMDs likely serve some function, perhaps forming a salt bridge that stabilizes 
dimers.   
 Zinc binding capability and other cofactors.  DHHC proteins were originally 
classified as zinc-finger proteins (87) and have been implicated in the transport of Mg2+ 
and Ca2+ ions (99, 100), however their ability to bind these metal ions has not been 
tested.  Inductively coupled plasma mass spectrometry (ICP-MS) could be used to 
determine the number and species of metal ions bound to DHHC protein.  It is probable 
that DHHC proteins contain at least one metal ion, likely binding residues with the 
DHHC-CRD domain, based on predictions and sequence conservation of residues known 
to bind metal-ions in other proteins.  Given that mammalian DHHC22 and yeast Ark1, 
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 Ark2, and Pfa5 lack a number of residues within the DHHC-CRD, it is possible they do 
not share this feature or bind a different metal species.  Reports describing the Mg2+ and 
Ca2+ transport capabilities of DHHC proteins were based on indirect assays and these 
alternative functions should be tested directly.  Reconstitution of DHHC proteins into 
liposomes and monitoring ion uptake by fluorescent chlelators or radiolabeled ions is one 
method of testing ion transport.      
 Discovering new inhibitors of DHHC-mediated protein S-acylation.  Inhibitors of 
protein S-acylation would be beneficial both as tools for studying DHHC proteins within 
cells and as potential pharmaceutical agents.  Having inhibitors with characterized 
methods of inhibition can aid in determining the order of substrate binding and product 
release.  For example, although the acyl chain is transferred from CoA to DHHC forming 
the acyl-intermediate, it is unknown whether the CoA leaves before protein substrate 
binding or after release of acylated protein.  Given the role of protein S-acylation and 
DHHC proteins in human diseases (Table 1.3), inhibitors may be clinically useful. 
 Additional screens are needed to find inhibitors of DHHC proteins.  The 
compounds tested in chapter 4 were representative of 4 chemical classes from the results 
of three inhibitor screens.  An additional 87 compounds were identified that belonged to 
these classes as well as 65 unique compounds not belonging to any of the chemoclasses 
(152).  Given that these compounds inhibited S-acylation in both a live cell-based screen 
and in PAT assays with crude cell membranes, they should be directly screened with 
purified proteins and in vitro PAT assays to determine their ability to inhibit DHHC 
proteins.   
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  High-content screening (HCS) is one strategy to find DHHC inhibitors.  A DHHC 
protein and/or one of its substrates fused to a monomeric fluorescent protein are 
expressed in cells.  The assay is based on a substrate displaying a different localization in 
the acylated and non-acylated states.  Following growth in a multi-well imaging plate, 
cells are treated with compounds and monitored for changes in fluorescence localization.  
Because of the complexities of cells and protein trafficking, compounds that altered 
localization would need to be validated with secondary screens.  A more detailed 
explanation of this approach is available (222). 
 Cell-free screens for the direct inhibition of DHHC proteins are also possible.  
Using purified DHHC proteins and either a protein or peptide substrate, the production of 
the reaction by-product CoA can be monitored.  One such assay has already been 
described and used to monitor the rates of palmCoA hydrolysis by Erf2 (175).  This 
approach involves coupling the production CoA to the reduction of NAD+ with α-
ketoglutarate dehydrogenase (α-KDH) and monitoring the reaction by NADH 
fluorescence emission.  Lead compounds would need to be validated by secondary screen 
for a number of reasons, including the possibility of inhibiting α-KDH.  Another cell-free 
screen possible with purified DHHC protein could be based on the ultra-high throughput 
screen (uHTS) developed to find inhibitors of fatty acid synthase and acetyl-CoA 
carboxylase (223).  The free thiol of CoA would react with 7-diethylamino-3-(4′-
maleimidylphenyl)-4-methylcoumarin (CPM), a compound that becomes fluorescent 
upon reaction with thiols.  It is unknown if CPM would react with thiols on the DHHC 
and protein substrate, however this was not the case for two enzymes previously tested.  
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 Unlike the coupled-assay, this latter approach involves only one enzyme and may present 
fewer challenges.  Compounds found through any screening assay will need further 
validation with secondary assays and subsequent characterization.  Additionally, 
structure-activity relationship (SAR) studies and the synthesis of analogous compounds 
will likely be needed to develop potent and specific inhibitors.  One feature of DHHC 
proteins to exploit to achieve inhibitor specificity is the acyl-chain length specificities 
demonstrated in this work.  
 
Concluding Remarks   
 With this work, I have shown that the currently available inhibitors for DHHC 
proteins are limited in potency and specificity and have further characterized the two 
most potent inhibitors available.  Uncovering the mechanism of DHHC proteins will aid 
in our ability to find better inhibitors as well as improve our understanding of this 
biologically important family of enzymes.  With that goal in mind, I have determined that 
DHHC proteins use a two-step ping-pong catalytic mechanism and display acyl-CoA 
specificity.  I hope that I have highlighted the contributions this work has made to a 
mechanistic understanding of DHHC proteins and the future work that is needed to 
further advance the protein S-acylation field. 
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 Appendix 
 
 
 
 
 
Characterization of DHHC9 in Ras Signaling  
and  
X-linked Mental Retardation 
 
 
 
 
 
 
 
The portion of this appendix related in FKBP12 and H-ras S-acylation was published in  
Ahearn, I. M., Tsai, F. D., Court, H., Zhou, M., Jennings, B. C., Ahmed, M., 
Fehrenbacher, N., Linder, M. E., and Philips, M. R.  2011.  FKBP12 binds to acylated H-
ras and promotes depalmitoylation.  Molecular Cell.  41:173-185.  My contributions 
appear in Figure 2.  
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 Introduction 
 The yeast protein Erf2 and its mammalian ortholog DHHC9 are protein S-
acyltransferases (PATs) for ras proteins.  Effector of ras function 2 (Erf2) as well as Erf4 
were identified in a genetic screen that required S-acylation of yeast Ras2 for survival 
(79).  These proteins were later shown to form a complex localized in the endoplasmic 
reticulum (80) and catalyze the acylation of Ras2 in vitro (81).  DHHC9 is the 
mammalian ortholog of Erf2, and along with its binding partner Golgi complex protein 
16 (GCP16), can catalyze the acylation of N- and H-ras (114).  Although the most likely 
candidate, to date no one has shown that DHHC9/GCP16 is responsible for acylating Ras 
in cells. The role of Erf4 and GCP16 is unknown, as no other DHHC proteins tested have 
required binding partners for activity.  DHHC9 has been associated with a number of 
human diseases (Table 1.3) including colorectal cancer (140, 142) and X-linked mental 
retardation (139).  This appendix highlights two projects related to DHHC9 mediated 
protein S-acylation.   
 
FKBP12 binds to acylated H-ras and promotes depalmitoylation.   
 Proline isomerization of H-ras affects its palmitoylation status.  Workers within 
the laboratory of Mark Philips noted that green fluorescent protein (GFP) tagged with last 
19 amino acids of H-ras recapitulated the full-length protein localization to both the 
Golgi and PM, but GFP tagged with the last 10 amino acids of H-ras localized only to the 
PM.  The last ten amino acids of H-ras (-GCMSCKCVLS.) has two cysteine residues 
known to be acylated and a CaaX box cysteine residue known to be prenylated.  
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 Acylation of these constructs was evaluated and the shorter GFP-10aa tail was shown to 
contain 2.5 times more radiolabeled palmitate than the GFP-19aa tail.  The additional 
nine residues (-LNPPDESGP-) in the longer GFP tail was rich in proline residues and led 
researchers to hypothesize that proline isomerization may regulate H-ras acylation and 
thereby trafficking.  
 Inhibiting prolyl isomerization was used to test this hypothesis.  Indeed, chemical 
inhibition of prolyl isomerization increased H-ras incorporation of radiolabeled palmitate 
up to 4-fold.  FK506-binding proteins (FKBPs) are one family of prolyl isomerases with 
FKBP12 being the best characterized, and it is inhibited by FK506.  Cells expressing the 
GFP-19aa tail of H-ras, when treated with FK506 or FKBP12 siRNA showed an increase 
in palmitate incorporation into GFP-19aa tail.  This was not observed when constructs 
lacking the proline residues or the GFP-10aa tail were expressed.  This increase in H-ras 
acylation when FKBP12 activity is suppressed could result from increased H-ras 
acylation, decreased H-ras deacylation, or both.  
 Directly testing whether FKBP12 altered H-ras acylation with purified 
components was my contribution to this work.  In a radiolabel-based in vitro PAT assay, 
DHHC9/GCP16 was used to palmitoylate the last 30aa of H-ras fused to GST, and the 
effects of FKBP12 and FK506 on this reaction were monitored.  The last 30aa rather than 
the last 19aa were used because purified preparations of farnesylated protein were 
available.  As shown in Figure A.1, inclusion of FKBP and/or FK506 into the reaction 
did not significantly alter the palmitoylation of GST-H-ras 30aa tail [PAT ID#617].  
Three similar experiments were performed to confirm the result: one with full-length N-
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 terminally tagged H-ras, His6-H-ras [PAT ID#621], and the remaining two with full-
length N-terminally tagged N-ras, His6-N-ras, including a titration of FKBP12 [PAT 
ID#621 and 625].  In no case was FKBP12 or FK506 able to alter DHHC9-mediated 
acylation of H-ras or N-ras.  While their effect could be through another DHHC protein 
in cells, it seemed more likely that FKBP12-mediated prolyl isomerization was 
decreasing deacylation of H-ras in cells.  
 Indeed, further experiments showed that FKBP12 affected the acylation level and 
localization of H-ras by increasing the deacylation of H-ras.  Co-immunoprecipitation 
experiments showed that FKBP12 bound to H-ras and N-ras, but not K-ras.  These 
interactions were blocked by FK506, 2-bromopalmitate, or mutation of the H-ras 
acylation sites (C181,184S), suggesting that acylation of H-ras was required for FKBP12 
binding.  Interestingly, FKBP12 did not require the C-terminal proline residues to co-IP 
with H-ras.  Additional functional studies showed that FBKP12 affected H-ras 
localization and retrograde trafficking from the PM to the Golgi.  Inhibition of FKBP12 
also resulted in greater GTP-loading of endogenous H-ras following EGF stimulation, 
consistent with inhibition of FKBP12 preventing depalmitoylation of H-ras and confining 
it to the PM adjacent upstream activators.  
 The role of FKBP12 in modulating Ras deacylation adds a new level to 
complexity to the regulation of Ras signaling.  It also raises several questions.  For 
example, how does soluble FKBP12 bind the membrane anchored acylated tail of H-ras 
and does the deacylation involve recruitment of acyl-protein thioesterases (APTs)?   
Another issued raised in the Preview for this article (224) is that FK506 is currently in 
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 use as an immunosuppressant and the work here may suggest FK506 has tumor 
promoting properties.  Given the challenges in monitoring prolyl isomerization, it 
remains to be determined whether the interplay between these two modifications is 
unique to Ras signaling or if prolyl cis-trans isomerization is a broader regulator of 
protein S-acylation.  
 
DHHC9 X-linked mental retardation mutant R148W displays reduced association 
with binding partner GCP16 and protein S-acyltransferase activity. 
 Genetic studies in humans have linked DHHC9 to X-linked mental retardation 
(XLMR) (139).  In order to find genes that cause XLMR, researchers characterized a 
cohort of 250 families in which at least two males have clinically diagnosed mental 
retardation with no known molecular cause.  Two truncations arising from a 4 bp 
insertion and a mutation causing alternative exon splicing, and two missense mutations 
were found in the ZDHHC9 gene.  The ZDHHC9 missense mutations resulted in proteins 
in which arginine 148 was changed to tryptophan (R148W) and proline 150 to serine 
(P150S).  These residues (R148 and P150) are conserved in DHHC9 orthologs from yeast 
to humans whereas overall sequence conservation is only 30%.  Both mutations are 
upstream of the canonical DHHC motif but still within the 51aa cysteine-rich domain.  
Our laboratory has begun to investigate the protein product of these mutations for 
differences in localization, PAT activity, and protein stability. 
 Given my expertise in analyzing DHHC PAT activity, I set out to determine if 
either of these point mutants affects the ability of DHHC9 to palmitoylate H-ras.  
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 Coworkers generated Baculoviruses to express R148W and P150S DHHC9-myc-His6 
proteins in Sf9 insect cells.  The P150S virus had poor expression levels and was not 
analyzed further.  The R148W DHHC9 was co-expressed with FLAG-GCP16 and 
purified over nickel resin (Figure A.2A).  Interestingly, unlike similar purifications with 
WT DHHC9, the binding partner GCP16 did not co-purify with R148W DHHC9.  
Another purification was attempted and compared to identical purifications of WT 
DHHC9 and both with and without GCP16.  As shown with nickel elutions in Figure 
A.2B, the R148W mutant displayed markedly reduced ability to co-purify GCP16 
relative to WT DHHC9.  Because the nickel elutions contained a number of 
contaminating proteins (not shown), we attempted to use myc-affinity resin to further 
purify all four samples.  The yield from such purifications was insufficient to use in 
activity assay, however immunoblotting of elutions did confirm again that WT DHHC9 
binds GCP16 whereas the R148W mutant does not (Figure A.2C).  Collectively, these 
results demonstrate that R148W DHHC9 displays reduced affinity for GCP16.   
 Using samples normalized for equal amounts of DHHC9 protein (Figure A.3B), I 
determined the ability of WT and R148W to palmitoylate H-ras using the standard 
radiolabel-based PAT assay (Figure A.3A).  WT DHHC9 with GCP16 robustly 
palmitoylated H-ras and autoacylated as previously described by our group (114).  
DHHC9 alone also autoacylated and palmitoylated H-ras but only at 30% of the levels 
observed when GCP16 was present.  This is unlike the original characterization of 
DHHC9 that showed no activity in the absence of GCP16 (114).  R148W alone and with 
GCP16 displayed a similar pattern to WT DHHC9 but with activities reduced by 50%.  
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 These results suggest that R148W DHHC9 has reduced PAT activity because of its 
reduced association with GCP16.  
 While these results do not provide a clear connection to XLMR, they do raise 
several new questions.  One difference between the original characterization of DHHC9 
PAT activity and those here is that in the earlier studies PAT assay buffers contained 
thiol-based reducing agents.  These reagents may have cleaved the acyl-enzyme thioester 
bonds present in the DHHC9 alone reactions here.  This would point to a role for GCP16 
in protecting the acyl-enzyme intermediate from hydrolysis.  Measuring acyl-CoA 
hydrolysis by WT and R148W could test this hypothesis.  R148W may display reduced 
PAT activity exclusively due to reduced GCP16 interaction or R148W may also be 
detrimental to catalysis.  Titration of GCP16 into the PAT reaction may differentiate 
these possibilities.  Interestingly, in the genetic screen in yeast that identified Erf2 as a 
Ras PAT, mutation of the R148 equivalent residue, R182, to alanine was not lethal.  This 
may suggest that in cells R148W retains enough PAT activity to acylate Ras and that 
defects in the acylation of other substrates are responsible for the XLMR phenotype.  
Techniques have been described to find protein substrates of individual DHHC proteins 
in mammalian cells (225); such methods may be needed to draw a connection between 
DHHC9 and XLMR.  Further, cell-based work examining protein localization and 
stability will also be important for characterizing these disease-associated mutations.  
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Figure A.1.  Palmitoylation of GST-H-ras 30aa tail in vitro using purified DHHC9/GCP16 and [3H]-
palmitoyl-CoA in the presence or absence of FK506 or recombinant FKBP12.  The indicated concen-
trations of reaction components were incubated at 25°C for 7 min.  Reactions were stopped with sample 
buffer and resolved by SDS-PAGE.  GST-H-ras 30aa tail bands were excised from one set of gels and 
processed for scintillation counting, while the other set of gels was processed for fluorography and exposed 
to film at -80°C [PAT ID#617]. 
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Figure A.2.  DHHC9 R148W displays reduced interaction with GCP16.  A, Purification of DHHC9-
myc-His6 R148W (pML1311) co-expressed with FLAG-GCP16 (pML756) over Ni-NTA resin. Sf9 cells 
were co-infected with viruses expressing both constructs, harvested, and lysed by nitrogen cavitation.  The 
soluble (S100) and membrane (P100) fractions were separated by centrifugation.  Detergent (DDM) was 
added to the membranes to extract DHHC9.  This detergent extract (S100.2) was diluted and loaded onto 
Ni-NTA resin.  The flow through (FT) was collected, the column was washed, and proteins were eluted with 
imidazole.  Immunoblotting was used to detect proteins within each sample [PAT ID#725].  B, WT and 
R148W DHHC9-myc-His6 were expressed with or without FLAG-GCP16 in Sf9 cells.  Purification with 
Ni-NTA resin was performed as in A.  Two volumes of a nickel elution were loaded for each sample [PAT 
ID#775].  C, Partially purified nickel elutions containing WT or R148W DHHC9-myc-His6 co-expressed 
with FLAG-GCP16 were bound to myc-affinity resin.  The flow through (FT) was collected, the column 
was washed, and proteins were eluted with myc peptide.  A sample of myc-affinity resin after elution was 
also run on the gel [PAT ID#737].  Purification and immunoblotting procedures were similar to those 
described in Chapters 3 and 4.
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Figure A.3.  DHHC9 R148W displays reduced protein S-acyltransferase activity for H-ras.  A,  
Normalized amounts of partially purified DHHC9-myc-His6 WT or R148W co-expressed with or without 
FLAG-GCP16 were incubated with His6-H-ras and radiolabeled palmCoA.  Fluorography exposures were 
at -80°C for the indicated time.  The longer exposure shows that WT DHHC9 alone and R148W DHHC9 
with GCP16 incorporated palmitate, albeit at low levels.  B, Immunoblot of the reactions in A to show that 
equal amounts of DHHC9 were assayed [PAT ID#785].  
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